Document:

EX-10.14

 Exhibit 10.14 

Certain identified information has been excluded from this exhibit because it is both not material and is the type 

that the registrant treats as private or confidential. Information that was omitted has been noted in this document 

with a placeholder identified by the mark “[***]”. 

PUBLIC HEALTH SERVICE 

PATENT LICENSE AGREEMENT – EXCLUSIVE/CO-EXCLUSIVE 

This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health 

Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health 

(“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration 

(“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”). 

This Cover Page identifies the Parties to this Agreement: 

The U.S. Department of Health and Human Services, as represented by 

The National Cancer Institute 
 an
Institute or Center (hereinafter referred to as the “IC”) of the 
 NIH 

and 
 Senti Biosciences, Inc. 

hereinafter referred to as the “Licensee”, 

having offices at 2 Corporate Drive, First Floor, South San Francisco, CA 94080, 

created and operating under the laws of Delaware. 

Tax ID No.: #81-2944208 

 For the IC internal use only: 

License Number: 
 License
Application Number: [***] 
 Serial Number(s) of Licensed Patent(s) or Patent Application(s): 

 

	 	(a)	 US Provisional Patent Application No.: 62/342,394 

HHS Ref. No.: E-133-2016-0-US-01 

Filing Date: May 27, 2016 

Current Status: Converted to PCT 
  

	 	(b)	 PCT/US2017/034,691 

HHS Ref. No.: E-133-2016-0-PCT-02 

Filing Date: May 26, 2017 

Current status: Expired 
  

	 	(c)	 P Patent Application No.:17729627.4 

HHS Ref. No.: E-133-2016-0-EP-03 

Filing Date: December 11, 2018 

Current status: Pending 
  

	 	(d)	 US Patent Application No.: 16/304,552 

HHS Ref. No.: E-133-2016-0-US-05 

Filing Date: November 26, 2018 

Current status: Pending 
  

	 	(e)	 Australia Patent Application No.: 2017271606 

HHS Ref. No.: E-133-2016-0-AU-06 

Filing Date: November 13, 2018 

Current status: Deferred 
  

	 	(f)	 Canadian Patent Application No.: 3025516 

HHS Ref. No.: E-133-2016-0-CA-07 

Filing Date: November 23, 2018 

Current status: Pending 
  

	 	(g)	 Japan Patent Application No.: 2018-561669 

HHS Ref. No.: E-133-2016-0-JP-08 

Filing Date: November 22, 2018 

Current status: Deferred 

Cooperative Research and Development Agreement (CRADA) Number (if a subject invention): N/A 

Additional Remarks: 
 Public
Benefit(s): 
 The public interest would be well served by an exclusive license for this technology since therapies are needed for the
treatment of FLT3 expressing cancers, among which are AML with a mortality rate of 10,000 per year and five-year survival of only 25%, and ALL, specifically pediatric ALL, which is a rare disease and as a pediatric indication has inherent
challenges in the development of new therapies. 
 This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of
this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E
(Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 2 of 29	  	[SentiBio]         [7-20-2020]

 The IC and the Licensee agree as follows: 

 

	1.	 BACKGROUND 

  

	 	1.1	 In the course of conducting biomedical and behavioral research, the IC investigators made inventions
that may have commercial applicability. 

  

	 	1.2	 The IC warrants that, by assignment of rights from the IC employees and other inventors,
HHS, on behalf of the Government, solely owns the rights in the Licensed Patent Rights as of the effective date of this Agreement. HHS also owns any tangible embodiments of the inventions claimed therein actually
reduced to practice by the IC. IC further warrants that to the best of its knowledge it has not granted and will not grant any licenses or rights within the Licensed Field of Use of this Agreement. 

 

	 	1.3	 The Secretary of HHS has delegated to the IC the authority to enter into this Agreement
for the licensing of rights to these inventions. 

  

	 	1.4	 The IC desires to transfer these inventions to the private sector through commercialization licenses to
facilitate the commercial development of products and processes for public use and benefit. 

  

	 	1.5	 The Licensee desires to acquire commercialization rights to certain of these inventions in order to
develop processes, methods, or marketable products for public use and benefit. 

  

	2.	 DEFINITIONS 

  

	 	2.1	 “Additional License” means an exclusive, co-exclusive or non-exclusive commercial license that
includes the Licensed Patent Rights and is granted to a Third Party (“Additional Licensee”) who is responsible for paying a share of patent expenses. [***]. 

 

	 	2.2	 “Affiliate(s)” means a corporation or other business entity, which directly or indirectly is
controlled by or controls, or is under common control with the Licensee. For this purpose, the term “control” shall mean ownership of more than fifty percent (50%) of the voting stock or other ownership interest of the
corporation or other business entity, or the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the corporation or other business entity. 

 

	 	2.3	 “Benchmarks” mean the performance milestones that are set forth in Appendix D.

  

	 	2.4	 “Combination Product” means a product that contains a Licensed Product(s) and at least
one other active therapeutic component or device other than a Licensed Product(s) that is not claimed or covered by the Licensed Patent Rights (“Other Product”). 

 

	 	2.5	 “Commercial Development Plan” means the written commercialization plan attached as Appendix E.

  

	 	2.6	 “CRADA” means a Cooperative Research and Development Agreement. 

 

	 	2.7	 “Fair Market Value” means the total amount or value expressed in U.S. dollars obtained by the
Licensee through the transfer or sale of its assets. 

  

	 	2.8	 “FDA” means the U.S. Food and Drug Administration, and any successor agency thereto.

  

	 	2.9	 “First Commercial Sale” means (a) with respect to a Licensed Product, the first
sale by or on behalf of the Licensee or any of its Affiliates or its sublicensees of such Licensed Product to a Third Party (other than a sublicensee) for end use of such Licensed Product in a regulatory
jurisdiction after regulatory approval has been granted for such Licensed Product in such regulatory jurisdiction or (b) the first practice of a Licensed Process by or on behalf of the Licensee or any of its Affiliates
or its sublicensees for a Third Party (other than a sublicensee), in each case (a) and (b) in exchange for cash or some equivalent to which value can be assigned for the purpose of determining Net Sales.

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 3 of 29	  	[SentiBio]         [7-20-2020]

	 	2.10	 “Government” means the Government of the United States of America. 

 

	 	2.11	 “IND” means (a) an Investigational New Drug Application as defined in the Federal Food,
Drug, and Cosmetic Act and applicable regulations promulgated thereunder by the FDA or (b) any similar application filed in a regulatory jurisdiction outside the U.S. 

 

	 	2.12	 “Indication” means a class of human disease or condition for which a separate NDA
(including any extensions or supplements) is required to be filed with the FDA. For clarity, if an NDA is approved for a Licensed Product in a particular Indication and patient population, a label expansion for such
Licensed Product to include such Indication in a different patient population shall not be considered a separate Indication. 

  

	 	2.13	 “Licensed Fields of Use” means the fields of use identified in Appendix B.

  

	 	2.14	 “Licensed Patent Rights” means: 

 

	 	(a)	 Patent applications (including provisional patent applications and PCT patent applications) or patents listed
in Appendix A, all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of these patents; 

 

	 	(b)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in 2.14(a): 

  

	 	(i)	 continuations-in-part of 2.14(a); 

 

	 	(ii)	 all divisions and continuations of these continuations-in-part; 

 

	 	(iii)	 all patents issuing from these continuations-in-part, divisions, and continuations; 

 

	 	(iv)	 priority patent application(s) of 2.14(a); and 

 

	 	(v)	 any reissues, reexaminations, and extensions of these patents; 

 

	 	(f)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in 2.14(a): all counterpart foreign and U.S. patent applications and patents to 2.14(a) and 2.14(b), including those listed in Appendix A; and 

  

	 	(g)	 Licensed Patent Rights shall not include 2.14(b) or 2.14(c) to the extent that they contain one
or more claims directed to new matter which is not the subject matter disclosed in 2.14(a). 

  

	 	2.8	 “Licensed Processes” means processes which, in the course of being practiced, would be within
the scope of one or more valid and unexpired claims of the Licensed Patent Rights in the country in which such processes are practiced that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of
a court of competent jurisdiction or revoked, disclaimed or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 4 of 29	  	[SentiBio]         [7-20-2020]

	 	2.9	 “Licensed Products” means tangible materials which, in the course of manufacture, use, sale,
or importation, would be within the scope of one or more valid and unexpired claims of the Licensed Patent Rights in the country of such manufacture, use, sale, or import, as applicable, that have not been held unpatentable, invalid or
unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction or revoked, disclaimed or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. 

 

	 	2.10	 “Licensed Territory” means the geographical area identified in Appendix B.

  

	 	2.11	 “NDA” means a New Drug Application of a Licensed Product filed with the FDA that
is required for marketing approval for such Licensed Product in the U.S. 

  

	 	2.12	 “Net Sales” means, with respect to any Licensed Product or Licensed Process, the
total gross receipts for sales of such Licensed Products or practice of such Licensed Processes by or on behalf of the Licensee or any of its Affiliates or its sublicensees to Third Parties, and from leasing,
renting, or otherwise making Licensed Products available to Third Parties without sale or other dispositions, whether invoiced or not, less the following: [***]. No deductions shall be made for commissions paid to individuals, whether
they are with independent sales agencies or regularly employed by the Licensee, or any sublicensee, and on its payroll, or for the cost of collections. Notwithstanding the foregoing, sales among Licensee, its Affiliates, or
their respective sublicensees shall not be included in the calculation of Net Sales, unless the purchaser is an end user of the Licensed Product or Licensed Process. The supply of Licensed Product or practice of
Licensed Process as samples for charitable or promotional purposes, for use in non-clinical or clinical trials, or any test or other studies reasonably necessary to comply with any applicable laws, or as is otherwise normal and customary in
the industry shall not be included in the computation of Net Sales. 

  

	 	2.13	 “[***]” means [***]. 

 

	 	2.14	 “[***]” means [***]. 

 

	 	2.15	 “Practical Application” means to manufacture in the case of a composition or product, to
practice in the case of a process or method, or to operate in the case of a machine or system; and in each case, under these conditions as to establish that the invention is being utilized and that its benefits are to the extent permitted by law or
Government regulations available to the public on reasonable terms. 

  

	 	2.16	 “Pro Rata Share” means one of the following: 

 

	 	(a)	 in instances where the Additional License(s) granted by IC recover a pre-determined percentage of
patent costs, [***] which recover a pre-determined percentage of patent costs. For example, if IC has granted an Additional License [***], then the Pro Rata Share would be [***]; 

 

	 	(b)	 in instances where the Additional Licenses granted by IC recover a full pro rata share of patent
prosecution costs, [***] granted by IC which recover a full pro rata share of patent prosecution costs [***] granted by IC which recover a full pro rata share of patent prosecution costs. For example, if IC has granted
[***] which recover a full pro rata share of patent prosecution costs, then the Pro Rata Share would be, [***], or [***]; or 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 5 of 29	  	[SentiBio]         [7-20-2020]

	 	(c)	 in instances where the Additional Licenses are granted according to the definition of both 2.23(a) and
2.23(b), the Pro Rata Share paid by Licensee will be the value derived from the Pro Rata Share [***] the value derived from the Pro Rata Share [***]. For example, if two (2) Additional Licenses are
granted wherein one (1) Additional License recovers [***] of patent prosecution costs and one (1) Additional License recovers a full pro rata share of patent prosecution costs, the Pro Rata Share would be ([***]).

  

	 	2.4	 “[***]” means, with respect to [***]. 

 

	 	2.5	 “[***]” means [***]. 

 

	 	2.6	 “Research License” means a nontransferable, nonexclusive license to make and to use the
Licensed Products or the Licensed Processes as defined by the Licensed Patent Rights for purposes of internal research and not for purposes of commercial manufacture or distribution or in lieu of purchase. 

 

	 	2.7	 “Sublicensing Revenue” means the Fair Market Value of any consideration actually
received by Licensee from a Third Party as consideration for the grant of rights to such Third Party under the Licensed Patent Rights. Sublicensing Revenue includes upfront fees, license maintenance fees, and
milestone payments, and other payments received by Licensee in consideration for any rights granted to Licensed Patent Rights under a sublicense agreement, but excludes [***]. If Licensee receives any payments from a sublicensee
in consideration for the grant of a sublicense under the Licensed Patent Rights and under other intellectual property licensed to such sublicensee, Licensee shall fairly allocate such amounts among all licensed intellectual property,
and only the portion allocated to the Licensed Patent Rights will be included in Sublicensing Revenue. Any dispute between the parties related to the allocation of Sublicensing Revenue will be resolved in accordance with
Paragraph 14.5. 

  

	 	2.8	 “Third Party” means a person or entity other than (i) Licensee or any of its
Affiliates or sublicensees and (ii) IC. 

  

	3.	 GRANT OF RIGHTS 

 

	 	3.1	 The IC hereby grants and the Licensee accepts, subject to the terms and conditions of this
Agreement, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the
Licensed Fields of Use—Exclusive (I in Appendix B) and to practice and have practiced any Licensed Process(es) in the Licensed Fields of Use—Exclusive (I in Appendix B). 

 

	 	3.2	 The IC hereby grants and the Licensee accepts, subject to the terms and conditions of this
Agreement, a co-exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the
Licensed Fields of Use – Co-Exclusive (II in Appendix B) and to practice and have practiced any Licensed Processes in the Licensed Fields of Use – Co-Exclusive (II in Appendix B). IC shall only grant one
(1) other co-exclusive license under the Licensed Patent Rights in the Licensed Fields of Use – Co-Exclusive (II in Appendix B) in the Licensed Territory to one (1) Additional Licensee
(“Co-Exclusive Licensee”). Upon termination of such co-exclusive license to the Co-Exclusive Licensee, IC shall promptly notify Licensee. 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 6 of 29	  	[SentiBio]         [7-20-2020]

	 	3.3	 If IC receives a license application with a complete commercial development plan from a Third Party for
commercial development of a Licensed Product(s) or Licensed Processes in the Licensed Fields of Use, as they pertain to Licensed Patent Rights for which the proposed commercial development is not reasonably addressed in
Licensee’s then-current Commercial Development Plan, IC shall notify Licensee, in writing, of the existence of the Third Party’s license application, identifying the scientific, clinical or technical
basis for its belief that such commercial development should occur. Upon receipt of such written notice, Licensee shall either: (a) within [***] amend its Commercial Development Plan in a manner reasonably acceptable to IC
to include a clinical research and development program for the proposed Third Party’s commercial development of said Licensed Product(s) or Licensed Processes including revised Benchmarks, acceptance of said
amendment to said Commercial Development Plan by IC shall take into account Licensee’s ongoing efforts and normal drug development standards for obtaining FDA approval for multiple Indication prophylactic and
therapeutic products; or (b) amend its Commercial Development Plan within [***] in a manner reasonably acceptable to IC to include an offer to enter into a commercially reasonable and customary joint pre-clinical research and
development program with the Third Party for the proposed Third Party’s commercial development of said Licensed Product(s) or Licensed Processes; or (c) within [***] initiate negotiations to grant a sublicense
under commercially reasonable and customary terms to said Third Party under Licensed Patent Rights; or both (b) and (c). If Licensee does not (a) amend its Commercial Development Plan in a manner reasonably
acceptable to IC to include a clinical research and development program for the proposed commercial development of said Licensed Product(s) or Licensed Processes of such Third Party including revised Benchmarks; or
(b) amend its Commercial Development Plan in a manner reasonably acceptable to IC to include a joint pre-clinical research and development program with the Third Party for the proposed commercial development of said
Licensed Product(s) or Licensed Processes; or (c) grant a sublicense within [***] under commercially reasonable terms to said Third Party under Licensed Patent Rights, for such commercial development; or both
(b) and (c), IC shall [***], or [***], and IC shall [***]. 

  

	 	3.4	 This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent
applications or patents of the IC other than the Licensed Patent Rights regardless of whether these patents are dominant or subordinate to the Licensed Patent Rights. 

 

	4.	 SUBLICENSING 

  

	 	4.1	 [***], the Licensee may enter into sublicensing agreements under the Licensed Patent Rights;
provided that (a) the IC shall review and [***] within [***] following the receipt of Licensee’s notice therefor, (b) the IC shall [***] of the sublicense agreement, and (c) if the IC does [***]
sublicensing agreement within the [***] period, the IC shall [***] sublicensing agreement and the Licensee shall have the right to enter into such sublicensing agreement. 

 

	 	4.2	 The Licensee agrees that any sublicenses granted by it shall provide that the obligations to the
IC of Paragraphs 5.1-5.4, 8.1, 10.1, 10.2, 12.5, and 13.8-13.10 of this Agreement shall be binding upon the sublicensee as if it were a party to this Agreement, to the extent applicable to the scope of the sublicense. The
Licensee further agrees to attach copies of these Paragraphs to all sublicense agreements. 

  

	 	4.3	 Any sublicenses granted by the Licensee shall provide for the termination of the sublicense, or the
conversion to a license directly between the sublicensees and the IC, at the option of the sublicensee, upon termination of this Agreement under Article 13. This conversion is subject to the IC approval (not to be unreasonably
withheld, conditioned, or delayed) and contingent upon acceptance by the sublicensee of the remaining provisions of this Agreement, to the extent applicable to the scope of the sublicense. 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 7 of 29	  	[SentiBio]         [7-20-2020]

	 	4.4	 The Licensee agrees to forward to the IC a complete copy (which may be redacted by
Licensee to remove Licensee’s or any sublicensee’s confidential information and/or know-how, but not for any redaction of financial or commercial terms of any sublicense agreement necessary for review to ensure
Licensee’s or any sublicensee’s compliance with its obligations under this Agreement) of each fully executed sublicense agreement postmarked within [***] of the execution of the agreement; provided that Licensee may
redact any commercially sensitive information which is not necessary for the IC to confirm (a) such sublicense agreement’s compliance with the terms of this Agreement or (b) the sublicensing royalties due under this
Agreement. To the extent permitted by law, the IC agrees to maintain each sublicense agreement in confidence. 

  

	5.	 STATUTORY AND NIH REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS 

 

	5.1		(a)	 the IC reserves on behalf of the Government an irrevocable, nonexclusive, nontransferable, royalty-free license for the
practice of all inventions licensed under the Licensed Patent Rights throughout the world by or on behalf of the Government and on behalf of any foreign government or international organization pursuant to any existing or future treaty
or agreement to which the Government is a signatory. Prior to the First Commercial Sale, at the IC’s reasonable request and to the extent available, the Licensee agrees to provide the IC with reasonable quantities of
the Licensed Products or materials made through the Licensed Processes for IC internal, pre-clinical research use only; provided that IC may be responsible for reimbursing Licensee for the cost and expense to
manufacture and supply such Licensed Products and/or materials. IC may not transfer any such Licensed Products or materials supplied pursuant to this Paragraph 5.1(a) to any organization, entity, or governmental agency other than IC
without the prior written consent of Licensee; and 

  

	 	(b)	 in the event that the Licensed Patent Rights are Subject Inventions made under CRADA, the
Licensee grants to the Government, pursuant to 15 U.S.C. §3710a(b)(1)(A), a nonexclusive, nontransferable, irrevocable, paid-up license to practice the Licensed Patent Rights or have the Licensed Patent Rights
practiced throughout the world by or on behalf of the Government. In the exercise of this license, the Government shall not publicly disclose trade secrets or commercial or financial information that is privileged or confidential
within the meaning of 5 U.S.C. §552(b)(4) or which would be considered as such if it had been obtained from a non-Federal party. Prior to the First Commercial Sale, at the IC’s request and to the extent available, the
Licensee agrees to provide the IC with reasonable quantities of the Licensed Products or materials made through the Licensed Processes for IC internal research use only; provided that IC may be responsible
for reimbursing Licensee for the cost and expense to manufacture and supply such Licensed Products and/or materials. IC may not transfer any such Licensed Products or materials supplied pursuant to this Paragraph 5.1(b)
to any organization, entity, or governmental agency other than IC without the prior written consent of Licensee. 

  

	 	5.2	 To the extent required under 35 U.S.C. §204, as amended, the Licensee agrees that products used or
sold in the United States embodying the Licensed Products or produced through use of the Licensed Processes shall be manufactured substantially in the United States, unless a written waiver is obtained in advance from the IC.

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 8 of 29	  	[SentiBio]         [7-20-2020]

	 	5.3	 The Licensee acknowledges that the IC may enter into future CRADAs under the Federal
Technology Transfer Act of 1986 that relate to the subject matter of this Agreement. The Licensee agrees not to unreasonably deny requests for a Research License from future collaborators with the IC when acquiring these
rights is necessary in order to make a CRADA project feasible. The IC shall notify Licensee of any such CRADA and Licensee may request an opportunity to join as a party to the proposed CRADA.

  

	5.4		(a)	 in addition to the reserved license of Paragraph 5.1, the IC reserves the right to grant Research Licenses directly or to
require the Licensee to grant Research Licenses on reasonable terms. The purpose of these Research Licenses is to encourage basic research, whether conducted at an academic or corporate facility. In order to safeguard the
Licensed Patent Rights, however, the IC shall consult with the Licensee and (i) the IC shall give the Licensee advance written notice to which the IC proposes to grant a Research License,
(ii) the IC shall provide the Licensee reasonable opportunity to raise objections thereto and comment thereon, to be provided within [***], and (iii) the IC shall consult with the Licensee to consider in good
faith the objections and comments of the Licensee, before granting to commercial entities a Research License or providing to them research samples of materials made through the Licensed Processes; and 

 

	 	(b)	 in exceptional circumstances, and in the event that the Licensed Patent Rights are Subject Inventions
made under a CRADA, the Government, pursuant to 15 U.S.C. §3710a(b)(1)(B), retains the right to require the Licensee to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use
the Licensed Patent Rights in the Licensed Field of Use on terms that are reasonable under the circumstances, or if the Licensee fails to grant this license, the Government retains the right to grant the license itself.
The exercise of these rights by the Government shall only be in exceptional circumstances and only if the Government determines: 

  

	 	(i)	 the action is necessary to meet health or safety needs that are not reasonably satisfied by the
Licensee; 

  

	 	(ii)	 the action is necessary to meet requirements for public use specified by Federal regulations, and these
requirements are not reasonably satisfied by the Licensee; or 

  

	 	(iii)	 the Licensee has failed to comply with an agreement containing provisions described in 15 U.S.C.
§3710a(c)(4)(B); and 

  

	 	(c)	 the determination made by the Government under this Paragraph 5.4 is subject to administrative appeal
and judicial review under 35 U.S.C. §203(b). 

  

	6.	 ROYALTIES AND REIMBURSEMENT 

 

	 	6.1	 The Licensee agrees to pay the IC a noncreditable, nonrefundable license issue royalty as set
forth in Appendix C. 

  

	 	6.2	 The Licensee agrees to pay the IC a nonrefundable minimum annual royalty as set forth in Appendix
C. 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 9 of 29	  	[SentiBio]         [7-20-2020]

	 	6.3	 The Licensee agrees to pay the IC earned royalties as set forth in Appendix C.

  

	 	6.4	 The Licensee agrees to pay the IC benchmark royalties as set forth in Appendix C.

  

	 	6.5	 The Licensee agrees to pay the IC sublicensing royalties as set forth in Appendix C.

  

	 	6.6	 A patent or patent application licensed under this Agreement shall cease to fall within the Licensed
Patent Rights for the purpose of computing earned royalty payments in any given country on the earliest of the dates that: 

  

	 	(a)	 the application has been abandoned and not continued; 

 

	 	(b)	 the patent expires or irrevocably lapses or has been revoked, disclaimed or admitted to be invalid or
unenforceable through reissue, re-examination, disclaimer or otherwise; or 

  

	 	(c)	 the patent has been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of
competent jurisdiction or administrative agency. 

  

	 	6.4	 No multiple royalties shall be payable because any Licensed Products or Licensed Processes are
covered by more than one of the Licensed Patent Rights. 

  

	 	6.5	 On sales of the Licensed Products by the Licensee made in other than an arm’s-length
transaction, the value of the Net Sales attributed under this Article 6 to this transaction shall be that which would have been received in an arm’s-length transaction in the same country, based on sales of like quantity and quality
products in the same country on or about the time of this transaction. 

  

	 	6.6	 The IC shall use reasonable efforts to require any Third Party obtaining an exclusive,
co-exclusive or non-exclusive license under the Licensed Patent Rights pursuant to an Additional License to pay a Pro Rata Share of unreimbursed patent expenses for the Licensed Patent Rights that are paid by the
IC prior to the effective date of this Agreement, pursuant to similar terms to those set forth for Licensee hereunder. With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of
all patent applications and patents included within the Licensed Patent Rights and paid by the IC prior to the effective date of this Agreement, the Licensee shall pay the IC, as an additional royalty, within [***]
of the IC’s submission of a statement and request for payment to the Licensee, an amount equivalent to [***] percent ([***]%) of these expenses previously paid by the IC. As of the [***], and subject to change prior to the
effective date of this Agreement, the total of such patent expenses equals approximately $[***]. 

  

	 	6.7	 The IC shall use reasonable efforts to require any Third Party obtaining an exclusive,
co-exclusive or non-exclusive license under the Licensed Patent Rights pursuant to an Additional License to pay a Pro Rata Share of patent expenses for the Licensed Patent Rights that are paid by the IC on or after
to the effective date of this Agreement, pursuant to similar terms to those set forth for Licensee hereunder. With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of all patent
applications and patents included within the Licensed Patent Rights and paid by the IC on or after the effective date of this Agreement, the IC, at its sole option, may require the Licensee: 

 

	 	(a)	 to pay the IC on an annual basis, within [***] of the IC’s submission of a statement and
request for payment, a royalty amount equivalent to the Pro Rata Share of these unreimbursed expenses paid during the previous calendar year(s); 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 10 of 29	  	[SentiBio]         [7-20-2020]

	 	(b)	 to pay the Pro Rata Share of these unreimbursed expenses directly to the law firm employed by the
IC to handle these functions. However, in this event, the IC and not the Licensee shall be the client of the law firm; or 

  

	 	(c)	 in limited circumstances, the Licensee may be given the right, but not the obligation, to assume
responsibility for the preparation, filing, prosecution, or maintenance of any patent application or patent included with the Licensed Patent Rights. In that event, the Licensee shall directly pay the attorneys or agents engaged to
prepare, file, prosecute, or maintain these patent applications or patents and shall provide the IC with copies of each invoice associated with these services as well as documentation that these invoices have been paid. 

 

	 	6.4	 The IC agrees, upon written request, to provide the Licensee with summaries of patent prosecution
invoices for which the IC has requested payment from the Licensee under Paragraphs 6.9 and 6.10. The Licensee agrees that all information provided by the IC related to patent prosecution costs shall be treated as
confidential commercial information and shall not be released to a Third Party except as required by law or a court of competent jurisdiction. 

  

	 	6.5	 The Licensee may elect to surrender its rights in any country of the Licensed Territory under any
of the Licensed Patent Rights upon [***] written notice to the IC and owe no payment obligation under Paragraph 6.10 for patent-related expenses paid in that country after [***] of the effective date of the written notice.

  

	7.	 PATENT FILING, PROSECUTION, AND MAINTENANCE 

 

	 	7.1	 Except as otherwise provided in this Article 7, the IC agrees to take responsibility for, but to consult
with, the Licensee in the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights and shall furnish copies of relevant patent-related documents to the
Licensee, including drafts of any substantive filing or response. IC shall provide relevant patent-related documents and drafts at least [***] in advance of intended submission and shall reasonably consider and implement
Licensee’s comments thereto. 

  

	 	7.2	 If the IC decides not to prepare, file, prosecute, or maintain any patent applications or patents
included in the Licensed Patent Rights, and Licensee is in good standing on the payment of patent reimbursement royalties, the IC shall notify Licensee at least [***] prior to any filing, payment, or other deadlines. In
such case, the Licensee and any Third Party to an Additional License (e.g. the Co-Exclusive Licensee) that is in good standing on the payment of patent reimbursement royalties shall promptly discuss which party shall have
the first right, but not the obligation, to assume, at its own expense, the responsibility for the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in such Licensed Patent Rights. If
Licensee assumes such responsibility, it shall, on an ongoing basis, promptly furnish copies of all patent-related documents to the IC. In this event, the Licensee shall, subject to the prior approval of the IC, select
registered patent attorneys or patent agents to provide these services on behalf of the Licensee and the IC. The IC shall provide appropriate powers of attorney and other documents necessary to undertake this action to the
patent attorneys or patent agents providing these services. The Licensee and its attorneys or agents shall consult with the IC in all aspects of the preparation, filing, prosecution and maintenance of patent applications and patents
included within the Licensed Patent Rights and shall provide the IC sufficient opportunity to comment on any document that the Licensee intends to file or to cause to be filed with the relevant intellectual property or patent
office. 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 11 of 29	  	[SentiBio]         [7-20-2020]

	 	7.3	 Each party shall promptly inform the other as to all matters that come to its attention that may affect the
preparation, filing, prosecution, or maintenance of the Licensed Patent Rights, and permit each other to provide comments and suggestions with respect to the preparation, filing, prosecution, and maintenance of the Licensed Patent
Rights, which comments and suggestions shall be considered by the other party. 

  

	8.	 RECORD KEEPING 

 

	 	8.1	 The Licensee agrees to keep accurate and correct records of the Licensed Products made, used,
sold, or imported and the Licensed Processes practiced under this Agreement appropriate to determine the amount of royalties due the IC. These records shall be retained for at least [***] following a given reporting period and
shall be available during normal business hours for inspection, at the expense of the IC, by an accountant or other designated auditor selected by the IC and reasonably acceptable to Licensee for the sole purpose of verifying
reports and royalty payments hereunder. The IC may conduct such audits no more than once per calendar year and may inspect records from a particular reporting period only once. The accountant or auditor shall sign Licensee’s
standard confidentiality agreement prior to the inspection and shall only disclose to the IC information relating to the accuracy of reports and royalty payments made under this Agreement. If an inspection shows an underreporting or
underpayment in excess of [***] for any [***] period, then the Licensee shall reimburse the IC for the cost of the inspection at the time the Licensee pays the unreported royalties, including any additional royalties as required
by Paragraph 9.8. All royalty payments required under this Paragraph shall be due within [***] of the date the IC provides to the Licensee notice of the payment due. If any inspection shows an overpayment by Licensee for any
period, then Licensee shall be permitted to credit the amount of such overpayment against any future amounts owed by Licensee under this Agreement. 

 

	9.	 REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS 

 

	 	9.1	 Prior to signing this Agreement, the Licensee has provided the IC with the Commercial
Development Plan in Appendix E, under which the Licensee intends to develop the Licensed Products or Licensed Processes with the intent of achieving the Practical Application. This Commercial Development Plan
is hereby incorporated by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D. 

  

	 	9.2	 The Licensee shall provide written annual reports on its product development progress or efforts to
commercialize under the Commercial Development Plan for the Licensed Fields of Use within [***] after December 31 of each calendar year. These progress reports shall include, but not be limited to: progress on research and
development, status of applications for regulatory approvals, manufacture and status of sublicensing, marketing, importing, and sales during the preceding calendar year, as well as, plans for the present calendar year. The IC also encourages
these reports to include information on any of the Licensee’s public service activities that relate to the Licensed Patent Rights. If [***], the Licensee shall [***]. In any annual report, the Licensee may propose
amendments to the Commercial Development Plan, acceptance of which by the IC may not be denied unreasonably. The Licensee agrees to [***] by the IC to evaluate the Licensee’s performance under this
Agreement. The Licensee may amend the Benchmarks at any time upon written approval by the IC. The IC shall not unreasonably withhold, condition or delay approval of any request of the Licensee to amend
the Commercial Development Plan, including the Benchmarks, and to extend the time periods of the Benchmarks if the request is supported by a reasonable showing by the Licensee of diligence in its performance under the
Commercial Development Plan and toward bringing the Licensed Products to the point of Practical Application as defined in 37 C.F.R. §404.3(d). The Licensee shall [***] in the plan originally submitted.

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 12 of 29	  	[SentiBio]         [7-20-2020]

	 	9.3	 The Licensee shall report to the IC the dates for achieving Benchmarks specified in
Appendix D and the First Commercial Sale in each country in the Licensed Territory within [***] of such occurrences. 

  

	 	9.4	 The Licensee shall submit to the IC, within [***] after each calendar half-year ending
June 30 and December 31, a royalty report, as described in the example in Appendix F, setting forth for the preceding half-year period the amount of the Licensed Products sold or Licensed Processes practiced by or on behalf
of the Licensee in each country within the Licensed Territory, the Net Sales, and the amount of royalty accordingly due. With each royalty report, the Licensee shall submit payment of earned royalties due. If no earned
royalties are due to the IC for any reporting period, the written report shall so state. The royalty report shall be certified as correct by an authorized officer of the Licensee and shall include a listing of all deductions made under
Paragraph 2.19 to determine Net Sales made under Article 6 to determine royalties due. The royalty report shall also [***] for the Licensed Product(s) sold in the United States. 

 

	 	9.5	 The Licensee agrees to forward semi-annually to the IC a copy of the relevant portion of these
reports received by the Licensee from its sublicensees during the preceding half-year period as shall be pertinent to a royalty accounting to the IC by the Licensee for activities under the sublicense. 

 

	 	9.6	 Royalties due under Article 6 shall be paid in U.S. dollars and payment options are listed in Appendix G. For
conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York foreign exchange rate quoted in The Wall Street Journal on the day that the payment is due. Any loss of exchange, value, taxes, or other expenses
incurred in the transfer or conversion to U.S. dollars shall be paid entirely by the Licensee. The royalty report required by Paragraph 9.4 shall be mailed to the IC at its address for Agreement Notices indicated on the
Signature Page. 

  

	 	9.7	 The Licensee shall be solely responsible for determining if any tax on royalty income is owed outside
the United States and shall pay the tax and be responsible for all filings with appropriate agencies of foreign governments. 

  

	 	9.8	 Additional royalties may be assessed by the IC on any payment that is more than [***] overdue at the
rate of [***] per month. This [***] per month rate may be applied retroactively from the original due date until the date of receipt by the IC of the overdue payment and additional royalties. The payment of any such additional royalties shall
not prevent the IC from exercising any other rights it may have as a consequence of the lateness of any payment. 

  

	 	9.9	 All plans and reports required by this Article 9 and marked “confidential” by the Licensee
shall, to the extent permitted by law, be treated by the IC as commercial and financial information obtained from a person and as privileged and confidential, and any proposed disclosure of these records by the IC under the Freedom of
Information Act (FOIA), 5 U.S.C. §552 shall be subject to the predisclosure notification requirements of 45 C.F.R. §5.65(d). 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 13 of 29	  	[SentiBio]         [7-20-2020]

	10.	 PERFORMANCE 

  

	 	10.1	 The Licensee shall use its reasonable commercial efforts to bring the Licensed Products and the
Licensed Processes to Practical Application. “Reasonable commercial efforts” for the purposes of this provision shall include reasonable efforts to adhere to the Commercial Development Plan in Appendix E and to perform
the Benchmarks in Appendix D. The efforts of any Affiliate or a sublicensee shall be considered the efforts of the Licensee. 

  

	 	10.2	 Upon the First Commercial Sale, until the expiration or termination of this Agreement, the
Licensee shall use its reasonable commercial efforts to make the Licensed Products and the Licensed Processes reasonably accessible to the United States public. 

 

	 	10.3	 The Licensee agrees, after its First Commercial Sale, to make commercially reasonable quantities
of the Licensed Products or materials produced through the use of the Licensed Processes available to patient assistance programs in the U.S., if applicable. 

 

	 	10.4	 The Licensee agrees, after its First Commercial Sale and as part of its marketing and product
promotion, to develop educational materials (e.g., brochures, website, etc.) directed to patients and physicians detailing the Licensed Products or medical aspects of the prophylactic and therapeutic uses of the Licensed Products.

  

	 	10.5	 The Licensee agrees to supply upon the IC’s request, to the Mailing Address for Agreement
Notices indicated on the Signature Page, the Office of Technology Transfer, NIH with inert samples of the Licensed Products or the Licensed Processes or their packaging for educational and display purposes only.

  

	11.	 INFRINGEMENT AND PATENT ENFORCEMENT 

 

	 	11.1	 The IC and the Licensee agree to notify each other promptly of each infringement or possible
infringement of the Licensed Patent Rights in the Licensed Field of Use – Exclusive or the Licensed Field of Use – Co-Exclusive, as well as, any facts which would be reasonably expected to affect the validity, scope,
or enforceability of the Licensed Patent Rights of which either party becomes aware. 

  

	 	11.2	 Upon the IC or Licensee’s receipt of a notice with respect to infringement or possible
infringement of the Licensed Patent Rights in the Licensed Field of Use – Exclusive in accordance with Paragraph 11.1, pursuant to this Agreement and the provisions of 35 U.S.C. Chapter 29, the Licensee may:

  

	 	(a)	 bring suit in its own name, at its own expense, and on its own behalf for infringement of presumably valid
claims in the Licensed Patent Rights; 

  

	 	(b)	 in any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever
nature recoverable for such infringement; or 

  

	 	(c)	 settle any claim or suit for infringement of the Licensed Patent Rights provided, however, that
Licensee may not enter into any settlement that admits the invalidity of any Licensed Patent Rights without the prior written consent of the IC. The IC and appropriate Government authorities shall have the first right
to take such actions in consultation with Licensee, and shall account to Licensee all collected damages, profits, payments, and rewards; and; and 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 14 of 29	  	[SentiBio]         [7-20-2020]

	 	(d)	 if the Licensee desires to initiate a suit for patent infringement, the Licensee shall notify the
IC in writing. If the IC does not notify the Licensee of its intent to pursue legal action within [***], the Licensee shall be free to initiate suit. The IC shall have a continuing right to intervene in the suit.
The Licensee shall take no action to compel the Government either to initiate or to join in any suit for patent infringement. The Licensee may request the Government to initiate or join in any suit if necessary to avoid
dismissal of the suit. Should the Government be made a party to any suit, [***] any reasonable costs, expenses, or fees which the Government incurs as a result of the motion or other action. In all cases, the Licensee agrees to
keep the IC reasonably apprised of the status and progress of any such litigation. Before the Licensee commences an infringement action, the Licensee shall notify the IC and give careful consideration to the views of the
IC and to any potential effects of the litigation on the public health in deciding whether to bring suit. Licensee shall have the right to be represented by its own counsel, at its own expense, in any such suit brought by the
IC. 

  

	 	11.5	 Upon the IC or Licensee’s receipt of a notice with respect to infringement or possible
infringement of the Licensed Patent Rights in the Licensed Field of Use – Co-Exclusive in accordance with Paragraph 11.1, and if the IC and appropriate Government authorities have elected not to not to take action,
the Licensee and the Co-Exclusive Licensee shall promptly discuss to determine which party shall have the right, but not the obligation, to assume, at its own expense, the responsibility for the enforcement of such Licensed Patent
Rights. If (a) Licensee assumes such responsibility, it shall have the right to enforce the Licensed Patent Rights under the terms and conditions set forth in Paragraphs 11.2(a)-11.2(d), mutatis mutandis; and
(b) the Co-Exclusive Licensee or any other Third Party assumes such responsibility, Licensee shall have the right (i) to join such enforcement action at it sole cost and expense, and (ii) if the Co-Exclusive
Licensee does not bring an enforcement action within [***] following such determination, to commence such action to enforce the Licensed Patent Rights under the terms and conditions set forth in Paragraphs 11.2(a)-11.2(d), mutatis
mutandis. 

  

	 	11.6	 In the event that a declaratory judgment action alleging invalidity or non-infringement of any of the
Licensed Patent Rights shall be brought against the Licensee or raised by way of counterclaim or affirmative defense in an infringement suit brought by the Licensee under Paragraph 11.2, pursuant to this Agreement and the
provisions of 35 U.S.C. Chapter 29 or other statutes, the Licensee may: 

  

	 	(a)	 defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the
Licensed Patent Rights; 

  

	 	(b)	 in any suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and award of
whatever nature recoverable for the infringement; and 

  

	 	(c)	 settle any claim or suit for declaratory judgment involving the Licensed Patent Rights, provided,
however, that Licensee may not enter into any settlement that admits the invalidity of any Licensed Patent Rights without the prior written consent of the IC. The IC and appropriate Government authorities shall
have the first right to take these actions and shall have a continuing right to intervene in the suit; and 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 15 of 29	  	[SentiBio]         [7-20-2020]

	 	(d)	 if the IC does not notify the Licensee of its intent to respond to the legal action within a
reasonable time, the Licensee shall be free to do so. The Licensee shall take no action to compel the Government either to initiate or to join in any declaratory judgment action. The Licensee may request the
Government to initiate or to join any such suit if necessary to avoid dismissal of the suit. Should the Government be made a party to any such suit by motion or any other action of the Licensee, the Licensee shall
reimburse the Government for any reasonable costs, expenses, or fees, which the Government incurs as a result of the motion or other action. If the Licensee elects not to defend against the declaratory judgment action, the
IC, at its option, may do so at its own expense. Licensee shall have the right to be represented by its own counsel, at its own expense, in any such defense by the IC. In all cases, the Licensee agrees to keep the
IC reasonably apprised of the status and progress of any litigation. Before the Licensee commences an infringement action, the Licensee shall notify the IC and give careful consideration to the views of the IC and
to any potential effects of the litigation on the public health in deciding whether to bring suit. 

  

	 	11.5	 In any action brought by Licensee under Paragraphs 11.2, 11.3 or 11.4, the expenses incurred by
Licensee, including costs, fees, attorney fees, and disbursements, shall be paid by the Licensee. The value of any recovery made by the Licensee through court judgment or settlement, after reimbursing Licensee’s
expenses incurred in such action, shall be [***]. 

  

	 	11.6	 The IC shall cooperate fully with the Licensee in connection with any action under Paragraphs
11.2, 11.3 or 11.4. The IC agrees promptly to provide access to all necessary documents and to render reasonable assistance in response to a request by the Licensee. 

 

	12.	 NEGATION OF WARRANTIES AND INDEMNIFICATION 

 

	 	12.1	 The IC offers no warranties other than those specified in Article 1. 

 

	 	12.2	 The IC does not warrant the validity of the Licensed Patent Rights and makes no representations
whatsoever with regard to the scope of the Licensed Patent Rights, or that the Licensed Patent Rights may be exploited without infringing other patents or other intellectual property rights of a Third Party.

  

	 	12.3	 THE IC MAKES NO WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE
OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE LICENSED PATENT RIGHTS OR TANGIBLE MATERIALS RELATED THERETO. 

  

	 	12.4	 The IC does not represent that it shall commence legal actions against any Third Party infringing
the Licensed Patent Rights. 

  

	 	12.5	 The Licensee shall indemnify and hold the IC, its employees, students, fellows, agents, and
consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage resulting from Third Party claims or demands to the extent arising
out of: 

  

	 	(a)	 the use by or on behalf of the Licensee, its sublicensees, directors or employees of any Licensed
Patent Rights; or 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 16 of 29	  	[SentiBio]         [7-20-2020]

	 	(b)	 the design, manufacture, distribution, or use of any Licensed Products, Licensed Processes or
materials by the Licensee, or other products or processes developed by Licensee or its sublicensees in connection with or arising out of the Licensed Patent Rights. 

except in each case of (a) and (b) to the extent arising out of the IC’s breach of this Agreement or the gross
negligence or willful misconduct of the IC or any its employees, students, fellows, agents, or consultants. 
  

	 	12.3	 The Licensee agrees to maintain a liability insurance program consistent with sound business practice.

  

	13.	 TERM, TERMINATION, AND MODIFICATION OF RIGHTS 

 

	 	13.1	 This Agreement is effective when signed by all parties, unless the provisions of Paragraph 14.16 are not
fulfilled, and shall extend, on a Licensed Product-by-Licensed Product (or Licensed Process-by-Licensed Process) and country-by-country basis, to the expiration of the last to expire of the Licensed Patent Rights
that claims such Licensed Product (or Licensed Process) in such country unless sooner terminated as provided in this Article 13. 

  

	 	13.2	 In the event that the Licensee is in default in the performance of any material obligations under this
Agreement, including but not limited to the obligations listed in Paragraph 13.5, and if the default has not been remedied within ninety (90) days after the date of notice in writing of the default, the IC may terminate this
Agreement by written notice and pursue outstanding royalties owed through procedures provided by the Federal Debt Collection Act. 

  

	 	13.3	 In the event that the Licensee becomes insolvent, files a petition in bankruptcy, has such a petition
filed against it, determines to file a petition in bankruptcy, or receives notice of a Third Party’s intention to file an involuntary petition in bankruptcy, the Licensee shall immediately notify the IC in writing.

  

	 	13.4	 The Licensee shall have a unilateral right to terminate this Agreement or any licenses in any
country or territory by giving the IC sixty (60) days written notice to that effect. 

  

	 	13.5	 The IC shall specifically have the right to terminate or modify, at its option, this Agreement,
if the IC reasonably determines that the Licensee: 

  

	 	(a)	 is not using commercially reasonable efforts to execute the Commercial Development Plan submitted with
its request for a license, as may be amended pursuant to Paragraph 9.2, and the Licensee cannot otherwise demonstrate to the IC’s satisfaction that the Licensee has taken, or can be expected to take within a reasonable
time, effective steps to achieve the Practical Application of the Licensed Products or the Licensed Processes; 

  

	 	(b)	 has not used commercially reasonable efforts to achieve the Benchmarks as may be modified under
Paragraph 9.2; 

  

	 	(c)	 has willfully made a false statement of, or willfully omitted a material fact in the license application or in
any report required by this Agreement; 

  

	 	(d)	 has committed a material breach of a covenant or agreement contained in this Agreement;

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 17 of 29	  	[SentiBio]         [7-20-2020]

	 	(e)	 is not keeping the Licensed Products or the Licensed Processes reasonably available to the public
after commercial use commences; or 

  

	 	(f)	 cannot reasonably justify a failure to comply with the domestic production requirement of Paragraph 5.2 unless
waived. 

  

	 	13.7	 In making the determination referenced in Paragraph 13.5, the IC shall take into account the normal
course of such commercial development programs conducted with sound and reasonable business practices and judgment and the annual reports submitted by the Licensee under Paragraph 9.2. Prior to invoking termination or modification of this
Agreement under Paragraph 13.5, the IC shall give written notice to the Licensee providing the Licensee specific notice of, and a ninety (90) day opportunity to respond to, the IC’s concerns as to the
items referenced in 13.5(a)-13.5(f). If the Licensee fails to alleviate the IC’s concerns as to the items referenced in 13.5(a)-13.5(f) or fails to develop a corrective action plan and initiate such corrective action plan to the
IC’s satisfaction, the IC may terminate this Agreement. 

  

	 	13.8	 When the public health and safety so require, and after written notice to the Licensee providing the
Licensee a [***] opportunity to respond, the IC shall have the right to require the Licensee to grant sublicenses to responsible applicants, on reasonable terms, in any Licensed Fields of Use under the Licensed Patent
Rights, unless the Licensee can reasonably demonstrate that the granting of the sublicense would not materially increase the availability to the public of the subject matter of the Licensed Patent Rights. The IC shall not
require the granting of a sublicense unless the responsible applicant has first negotiated in good faith with the Licensee. 

  

	 	13.9	 The IC reserves the right according to 35 U.S.C. §209(d)(3) to terminate or modify this
Agreement if it is determined that this action is necessary to meet the requirements for public use specified by federal regulations issued after the date of the license and these requirements are not reasonably satisfied by the
Licensee. 

  

	 	13.10	 Within [***] of receipt of written notice of the IC’s [***] to modify or terminate this
Agreement, the Licensee may, consistent with the provisions of 37 C.F.R. §404.11, appeal the decision by written submission to the designated IC official or designee. The decision of the designated IC official or
designee shall be the final agency decision. The Licensee may thereafter exercise any and all administrative or judicial remedies that may be available. 

 

	 	13.11	 Within [***] of expiration or termination of this Agreement under this Article 13, a final report shall
be submitted by the Licensee. Any royalty payments, including those incurred but not yet paid (such as the full minimum annual royalty), and those related to patent expenses, due to the IC shall become immediately due and payable upon
termination or expiration. If terminated under this Article 13, sublicensees may elect to convert their sublicenses to direct licenses with the IC pursuant to Paragraph 4.3. Unless otherwise specifically provided for under this
Agreement, upon termination or expiration of this Agreement, the Licensee shall return all Licensed Products or other IC-provided materials included within the Licensed Patent Rights to the IC or
provide the IC with written certification of the destruction thereof. The Licensee may not be granted additional IC licenses if the final reporting requirement is not fulfilled. 

 

	14.	 GENERAL PROVISIONS 

 

	 	14.1	 Neither party may waive or release any of its rights or interests in this Agreement except in writing.
The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right by such party or excuse a similar subsequent failure to perform any
of these terms or conditions by the other party. 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 18 of 29	  	[SentiBio]         [7-20-2020]

	 	14.2	 This Agreement constitutes the entire agreement between the parties relating to the subject matter of
the Licensed Patent Rights, the Licensed Products and the Licensed Processes, and all prior negotiations, representations, agreements, and understandings are merged into, extinguished by, and completely expressed by this
Agreement. 

  

	 	14.3	 The provisions of this Agreement are severable, and in the event that any provision of this
Agreement shall be determined to be invalid or unenforceable under any controlling body of law, this determination shall not in any way affect the validity or enforceability of the remaining provisions of this Agreement.

  

	 	14.4	 If either party desires a modification to this Agreement, the parties shall, upon reasonable notice of
the proposed modification by the party desiring the change, confer in good faith to determine the desirability of the modification. No modification shall be effective until a written amendment is signed by the signatories to this Agreement or
their designees. 

  

	 	14.5	 The construction, validity, performance, and effect of this Agreement shall be governed by Federal law
as applied by the Federal courts in the District of Columbia. 

  

	 	14.6	 All Agreement notices required or permitted by this Agreement shall be in writing and given by
prepaid, first class, registered or certified mail or by an express/overnight delivery service provided by a commercial carrier, properly addressed to the other party at the address designated on the following Signature Page, or to another address
as may be designated in writing by such other party. Agreement notices shall be considered timely if such notices are received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal
Service postmark or dated receipt from a commercial carrier. Parties should request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be
acceptable as proof of timely mailing. 

  

	 	14.7	 This Agreement shall not be assigned or otherwise transferred (including any transfer by legal process
or by operation of law, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure or order of court), except to the Licensee’s Affiliate(s) (for which the consent of IC shall not be required), without the
prior written consent of the IC, not to be unreasonably withheld, conditioned or delayed. For any assignment other than to an Affiliate the IC will have a period of [***] from the date that it receives written notice from the
Licensee of a proposed assignment, to approve or reject the proposed assignment and such approval shall not be unreasonably withheld; the approval or rejection must be in writing and delivered to Licensee’s official address for
Agreement notices. If the IC does not reject the proposed assignment within the [***] period, the IC shall be deemed to have given its approval of such assignment and the Licensee shall have the right to enter into such
assignment agreement. The parties agree that the identity of the parties is material to the formation of this Agreement and that the obligations under this Agreement are nondelegable. In the event that the IC approves a proposed
assignment, the Licensee shall [***] for any assignment of this Agreement, within [***] of the assignment (it being understood that [***]). 

  

	 	14.8	 The Licensee agrees in its use of any IC-supplied materials to comply with all applicable
statutes, regulations, and guidelines, including NIH and HHS regulations and guidelines. The Licensee agrees not to use the materials for research involving human subjects or clinical trials in the United States without
complying with 21 C.F.R. Part 50 and 45 C.F.R. Part 46. The Licensee agrees not to use the materials for research involving human subjects or clinical trials outside of the United States without notifying the IC, in writing, of the
research or trials and complying with the applicable regulations of the appropriate national control authorities. Written notification to the IC of such research involving human subjects or clinical trials outside of the United States shall
be given no later than [***] prior to commencement of the research or trials. 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 19 of 29	  	[SentiBio]         [7-20-2020]

	 	14.9	 The Licensee acknowledges that it is subject to and agrees to abide by the United States laws and
regulations (including the Export Administration Act of 1979 and Arms Export Control Act) controlling the export of technical data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of these items may
require a license from the appropriate agency of the U.S. Government or written assurances by the Licensee that it shall not export these items to certain foreign countries without prior approval of this agency. The IC neither
represents that a license is or is not required or that, if required, it shall be issued. 

  

	 	14.10	 The Licensee agrees to mark the Licensed Products or their packaging sold in the United States
with all applicable U.S. patent numbers and similarly to indicate “Patent Pending” status, to the extent required by applicable laws. All the Licensed Products manufactured in, shipped to, or sold in other countries shall be marked
in a manner necessary to preserve the IC’s patent rights in those countries. 

  

	 	14.11	 By entering into this Agreement, the IC does not directly or indirectly endorse any product or
service provided, or to be provided, by the Licensee whether directly or indirectly related to this Agreement. The Licensee shall not state or imply that this Agreement is an endorsement by the Government, the
IC, any other Government organizational unit, or any Government employee. Additionally, the Licensee shall not use the names of the IC, the FDA, the HHS or the Government or their employees in
any advertising, promotional, or sales literature without the prior written approval of the IC. 

  

	 	14.12	 The parties agree to attempt to settle amicably any controversy or claim arising under this Agreement or
a breach of this Agreement, except for appeals of modifications or termination decisions provided for in Article 13. The Licensee agrees first to appeal any unsettled claims or controversies to the designated IC official, or
designee, whose decision shall be considered the final agency decision. Thereafter, the Licensee may exercise any administrative or judicial remedies that may be available. 

 

	 	14.13	 Nothing relating to the grant of a license, nor the grant itself, shall be construed to confer upon any person
any immunity from or defenses under the antitrust laws or from a charge of patent misuse, and the acquisition and use of rights pursuant to 37 C.F.R. Part 404 shall not be immunized from the operation of state or Federal law by reason of the source
of the grant. 

  

	 	14.14	 Any formal recordation of this Agreement required by the laws of any Licensed Territory as a
prerequisite to enforceability of the Agreement in the courts of any foreign jurisdiction or for other reasons shall be carried out by the Licensee at its expense, and appropriately verified proof of recordation shall be promptly
furnished to the IC. 

  

	 	14.15	 Paragraphs 2.14-2.16, 2.28, 4.3, 8.1, 9.5-9.8 (solely with respect to payments incurred but not yet paid prior
to the effective date of expiration or termination), 12.1-12.5, 13.9, 13.10, 14.12 and 14.15 of this Agreement shall survive termination of this Agreement. 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 20 of 29	  	[SentiBio]         [7-20-2020]

	 	14.16	 The terms and conditions of this Agreement shall, at the IC’s sole option, be considered by
the IC to be withdrawn from the Licensee’s consideration and the terms and conditions of this Agreement, and the Agreement itself to be null and void, unless this Agreement is executed by the Licensee
and a fully executed original is received by the IC within [***] from the date of the IC’s signature found at the Signature Page. 

SIGNATURES BEGIN ON NEXT PAGE 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 21 of 29	  	[SentiBio]         [7-20-2020]

 NIH PATENT LICENSE AGREEMENT – EXCLUSIVE 

SIGNATURE PAGE 
 For the IC: 

 

					
	 /s/ Richard U. Rodriguez-S
	  	        	  	7-20-20
	Richard U. Rodriguez	  		  	Date
	Associate Director	  		  	
	Technology Transfer Center	  		  	
	National Cancer Institute	  		  	
	National Institutes of Health	  		  	

 Mailing Address or E-mail Address for Agreement notices and reports: 

License Compliance and Administration 
 Monitoring &
Enforcement 
 Office of Technology Transfer 
 National
Institutes of Health 
 6011 Executive Boulevard, Suite 325 

Rockville, Maryland 20852-3804 U.S.A. 
 E-mail:
LicenseNotices_Reports@mail.nih.gov 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 22 of 29	  	[SentiBio]         [7-20-2020]

 For the Licensee (Upon, information and belief, the undersigned expressly certifies or affirms that
the contents of any statements of the Licensee made or referred to in this document are truthful and accurate.): 
  

					
	by:	  	        	  	
			
	 /s/ Curt Herberts
	  		  	 7/25/2020

	Signature of Authorized Official	  		  	Date
			
	 Curt Herberts
	  		  	
	Printed Name	  		  	
			
	 CFO and CBO
	  		  	
	Title	  		  	

  

					
	        I.	 	Official and Mailing Address for Agreement notices:
			
		 	 [***]
	  	
		 	Name	  	
			
		 	 [***]
	  	
		 	Title	  	
			
		 	Mailing Address	  	
			
		 	 [***]
	  	
			
		 	  
	  	
			
		 	  
	  	
		
		 	Email Address:
    [***]                                    
            
		
		 	Phone:
                  [***]                      
                          
		
	        II.	 	Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty payments)
			
		 	 [***]
	  	
		 	Name	  	
			
		 	 [***]
	  	
		 	Title	  	
			
		 	Mailing Address:	  	
			
		 	 [***]
	  	

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 23 of 29	  	[SentiBio]         [7-20-2020]

					
		 	                                    
                                         
           
		
		 	                                    
                                    
		
	        	 	Email Address:
    [***]                                    
            
		
		 	Phone:
                  [***]                      
                          

 Any false or misleading statements made, presented, or submitted to the Government, including any relevant omissions,
under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§3801-3812 (civil liability) and 18 U.S.C. §1001
(criminal liability including fine(s) or imprisonment). 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 24 of 29	  	[SentiBio]         [7-20-2020]

 APPENDIX A – PATENT(S) OR PATENT APPLICATION(S) 

Patent(s) or Patent Application(s): 
  

	 	(a)	 US Provisional Patent Application No.: 62/342,394 [HHS Ref. No.: E-133-2016-0-US-01]

 Filing Date: May 27, 2016 
  

	 	(b)	 PCT/US2017/034,691 [HHS Ref. No.: E-133-2016-0-PCT-02] 

Filing Date: May 26, 2017 
  

	 	(c)	 EP Patent Application No.:17729627.4 [HHS Ref. No.: E-133-2016-0-EP-03] 

Filing Date: December 11, 2018 
  

	 	(d)	 US Patent Application No.: 16/304,552 [HHS Ref. No.: E-133-2016-0-US-05] 

Filing Date: November 26, 2018 
  

	 	(e)	 Australia Patent Application No.: 2017271606 [HHS Ref. No.: E-133-2016-0-AU-06 

Filing Date: November 13, 2018 
  

	 	(f)	 Canadian Patent Application No.: 3025516 [HHS Ref. No.: E-133-2016-0-CA-07] 

Filing Date: November 23, 2018 
  

	 	(g)	 Japan Patent Application No.: 2018-561669 [HHS Ref. No.: E-133-2016-0-JP-08] 

Filing Date: November 22, 2018 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 25 of 29	  	[SentiBio]         [7-20-2020]

 APPENDIX B – LICENSED FIELDS OF USE AND TERRITORY 

 

	I.	 Licensed Fields of Use – Exclusive: 

The development of a universal or split chimeric antigen receptor (CAR)-based immunotherapy using autologous or allogeneic human lymphocytes (T
cells or NK cells) transduced with lentiviral vectors, for the prophylaxis or treatment of cancers expressing FMS-like tyrosine kinase 3 (FLT3; also known as CD135), wherein the CAR construct binds to the FLT3-binding domain referenced as NC7 in the
invention, but NC7 is not included in the CAR construct, and in any case excluding FLT3-specific CAR -based immunotherapies wherein the CAR construct comprises the FLT3-binding domain referenced as NC7 in the invention as well as an intracellular
signaling domain. 
  

	II.	 Licensed Fields of Use – Co-Exclusive 

 

	 	(a)	 The development of a multi-specific FLT3 CAR-based immunotherapy using autologous or allogeneic human
lymphocytes (T cells or NK cells) transduced with lentiviral vectors, wherein the viral transduction leads to the expression of a CAR that targets FLT3 (comprised of the FLT3-binding domain referenced as NC7 in the invention as well as an
intracellular signaling domain), for the prophylaxis or treatment of FLT3-expressing cancers. [***] 

  

	 	(b)	 The development of a FLT3-specific Regulated or Switch or Logic-Gated CAR-based immunotherapy using autologous
or allogeneic human lymphocytes (T cells or NK cells) transduced with lentiviral vectors, wherein the viral transduction leads to the expression of a CAR that targets FLT3 (comprised of the FLT3-binding domain referenced as NC7 in the invention as
well as an intracellular signaling domain), for the prophylaxis or treatment of FLT3-expressing cancers. [***] 

  

	III.	 Licensed Territory: 

Worldwide 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 26 of 29	  	[SentiBio]         [7-20-2020]

 APPENDIX C – ROYALTIES 

Royalties: 
 I. The Licensee agrees to pay to the IC a
noncreditable, nonrefundable license issue royalty in the amount of seventy-five thousand dollars ($75,000) [***]. 

  

					
	[***].	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 27 of 29	  	[SentiBio]         [7-20-2020]

 APPENDIX D – BENCHMARKS AND PERFORMANCE 

[***] 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 28 of 29	  	[SentiBio]         [7-20-2020]

 APPENDIX E – COMMERCIAL DEVELOPMENT PLAN 

[***]. 
 Figure 1: [***] 

Figure 2: [***] 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 29 of 29	  	[SentiBio]         [7-20-2020]

 APPENDIX F – EXAMPLE ROYALTY REPORT 

Required royalty report information includes: 
  

	 	•	 	 License reference number (L-XXX-200X/0) 

 

	 	•	 	 Reporting period 

  

	 	•	 	 Catalog number and units sold of each Licensed Product (domestic and foreign) 

 

	 	•	 	 Gross Sales per catalog number per country 

 

	 	•	 	 Total Gross Sales 

  

	 	•	 	 Itemized deductions from Gross Sales 

 

	 	•	 	 Total Net Sales 

  

	 	•	 	 Earned Royalty Rate and associated calculations 

 

	 	•	 	 Gross Earned Royalty 

  

	 	•	 	 Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made 

 

	 	•	 	 Net Earned Royalty due 

Example 
  

									
	 Catalog Number
	  	Product Name	  	Country	  	Units Sold	  	Gross Sales (US$)
	 1
	  	A	  	US	  	250	  	62,500
	 1
	  	A	  	UK	  	32	  	16,500
	 1
	  	A	  	France	  	25	  	15,625
	 2
	  	B	  	US	  	0	  	0
	 3
	  	C	  	US	  	57	  	57,125
	 4
	  	D	  	US	  	12	  	1,500

  

					
	 Total Gross Sales
	  	 	153,250	 
	 Less Deductions:
	  			
	 Freight
	  	 	3,000	 
	 Returns
	  	 	7,000	 
	 Total Net Sales
	  	 	143,250	 
	 Royalty Rate
	  	 	8%	 
	 Royalty Due
	  	 	11,460	 
	 Less Creditable Payments
	  	 	10,000	 
	 Net Royalty Due
	  	 	1,460	 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 30 of 29	  	[SentiBio]         [7-20-2020]

 APPENDIX G – ROYALTY PAYMENT OPTIONS 

New Payment Options Effective March 2018 

The License Number MUST appear on payments, reports and correspondence. 

Credit and Debit Card Payments: Credit and debit card payments can be submitted for amounts up to $24,999. Submit your payment through the U.S.
Treasury web site located at: https://www.pay.gov/public/form/start/28680443. 
 Automated Clearing House (ACH) for payments through U.S. banks
only 
 The IC encourages its licensees to submit electronic funds transfer payments through the Automated Clearing House (ACH). Submit your ACH
payment through the U.S. Treasury web site located at: https://www.pay.gov/public/form/startJ28680443. Please note that the IC “only” accepts ACH payments through this U.S. Treasury web site. 

Electronic Funds Wire Transfers: The following account information is provided for wire payments. In order to process payment via Electronic Funds
Wire Transfer sender MUST supply the following information within the transmission: 
 Drawn on a U.S. bank account via FEDWIRE: 

Please provide the following instructions to your Financial Institution for the remittance of Fedwire payments to the NIH ROYALTY FUND. 

[***] 
 Agency Contacts: Office of Technology Transfer
(OTT) [***] 
 Drawn on a foreign bank account via FEDWIRE: 

The following instructions pertain to the Fedwire Network. Deposits made in US Dollars (USD). 

Should your remitter utilize a correspondent US domestic bank in transferring electronic funds, the following Fedwire instructions are applicable. 

[***] 
 Agency Contacts: 

Office of Technology Transfer (OTT)        (301) 496-7057 OTT-Royalties@mail.nih.gov 

Checks 
 All checks should be made payable to
“NIH Patent Licensing” 
 Checks drawn on a U.S. bank account and sent by US Postal Service should be sent directly to the following
address: 
 [***] 
 Checks drawn on a U.S. bank
account and sent by overnight or courier should be sent to the following address: 
 [***] 

Checks drawn on a foreign bank account should be sent directly to the following address: 

[***] 

  

					
	[***]	  		  	
	    	  		  	
	CONFIDENTIAL	  		  	
	NIH Patent License Agreement – Exclusive	  		  	
	Model 10-2015	  	Page 31 of 29	  	[SentiBio]         [7-20-2020]EX-10.15

 Exhibit 10.15 

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant
treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

PUBLIC HEALTH SERVICE 

PATENT LICENSE AGREEMENT – EXCLUSIVE 

This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service
(“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug
Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”). 

This Cover Page identifies the Parties to this Agreement: 

The U.S. Department of Health and Human Services, as represented by 

The National Cancer Institute 
 an
Institute or Center (hereinafter referred to as the “IC”) of the 
 NIH 

and 
 Senti Biosciences, Inc.,

 hereinafter referred to as the “Licensee”, 

having offices at 
 2 Corporate
Dr., First Floor, South San Francisco, CA 94080, 
 And operating under the laws of Delaware. 

Tax ID No.: 81-2944208 

 For the IC internal use only: 

License Number: 
 License
Application Number: [***] 
 Serial Number(s) of Licensed Patent(s) or Patent Application(s): 

 

	I.	
E-136-2012-0
Technology 

  

	 	a)	 U.S. Provisional Patent Application 61/654,232 entitled “High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof” [HHS Ref.
E-136-2012-0-US-01], 

 

	 	b)	 PCT Patent Application PCT/US2013/043633 entitled “High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof” [HHS Ref.
E-136-2012-0-PCT-02], 

 

	 	c)	 Chinese Patent 104520331 entitled “High-affinity Monoclonal Antibodies To
Glypican-3 And Use Thereof” [HHS Ref. E-136-2012-0-CN-03], 

  

	 	d)	 Japanese Patent 6494507 entitled “High-affinity Monoclonal Antibodies To
Glypican-3 And Use Thereof” [HHS Ref. E-136-2012-0-JP-04], 

  

	 	e)	 South Korean Patent Application 10-2014-7037046 entitled
“High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof” [HHS Ref. E-136-2012-0-KR-05], 

  

	 	f)	 Singapore Patent 11201407972R entitled “High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof” [HHS Ref.
E-136-2012-0-SG-06], and 

 

	 	g)	 United States Patent 9,409,994 entitled “High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof” [HHS Ref.
E-136-2012-0-US-07]. 

Cooperative Research and Development Agreement (CRADA) Number (if a subject invention): None 

Public Benefit(s): Liver cancer is the third leading cause of cancer-related deaths, and there are few effective therapeutic options. The grant
of this license could need to the development of a new therapeutic option, thereby meeting an unmet public health need. 
 This Patent License Agreement,
hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C
(Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). 

 The IC and the Licensee agree as follows: 

 

	1.	 BACKGROUND 

  

	 	1.1	 In the course of conducting biomedical and behavioral research, the IC investigators made inventions
that may have commercial applicability. 

  

	 	1.2	 The IC warrants that, by assignment of rights from IC employees and other inventors, HHS,
on behalf of the Government, solely owns the Licensed Patent Rights at the time of execution of this Agreement. HHS also owns any tangible embodiments of these inventions claimed therein actually reduced to practice by
the IC. IC further warrants that IC has not granted and will not grant any licenses or rights under the Licensed Patent Rights that are inconsistent with the license granted to Licensee hereunder.

  

	 	1.3	 The Secretary of HHS has delegated to the IC the authority to enter into this Agreement
for the licensing of rights to these inventions. 

  

	 	1.4	 The IC desires to transfer these inventions to the private sector through commercialization licenses to
facilitate the commercial development of products and processes for public use and benefit. 

  

	 	1.5	 The Licensee desires to acquire commercialization rights to certain of these inventions in order to
develop processes, methods, or marketable products for public use and benefit. 

  

	2.	 DEFINITIONS 

  

	 	2.1	 “Additional License” means an exclusive or
non-exclusive license that includes the Licensed Patent Rights and is granted to a Third Party who is responsible for paying a share of patent expenses, and wherein the exclusive or non-exclusive license has a Licensed Field(s) of Use directed to therapeutic applications. [***]. 

  

	 	2.2	 “Affiliate(s)” means a corporation or other business entity, which directly or indirectly is
controlled by or controls, or is under common control with the Licensee. For this purpose, the term “control” shall mean ownership of more than fifty percent (50%) of the voting stock or other ownership interest of the corporation
or other business entity, or the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the corporation or other business entity. 

 

	 	2.3	 “Benchmarks” mean the performance milestones that are set forth in Appendix D.

  

	 	2.4	 “Commercial Development Plan” means the written commercialization plan attached as Appendix E.

  

	 	2.5	 “CRADA” means a Cooperative Research and Development Agreement. 

 

	 	2.6	 “Fair Market Value” means the total amount or value expressed in U.S. dollars obtained by the
Licensee through the transfer or sale of its assets. 

  

	 	2.7	 “FDA” means the U.S. Food and Drug Administration, and any successor agency thereto.

  

	 	2.8	 “First Commercial Sale” means (a) the first sale. by or on behalf of the Licensee,
any of its Affiliates, or its sublicensees, of a Licensed Product to a Third Party (other than a sublicensee) for end use of such Licensed Product in a regulatory jurisdiction after regulatory approval has been granted
for such Licensed Product in such regulatory jurisdiction or (b) the first practice of a Licensed Process, by or on behalf of the Licensee, any of its Affiliates, or its sublicensees, for a Third Party
(other than a sublicensee), in each case (a) and (b) in exchange for cash or some equivalent to which value can be assigned for the purpose of determining Net Sales. 

	 	2.9	 “Government” means the Government of the United States of America. 

 

	 	2.10	 “IND” means (a) an Investigational New Drug Application as defined in the Federal
Food, Drug, and Cosmetic Act and applicable regulations promulgated thereunder by the FDA or (b) any similar application filed in a regulatory jurisdiction outside the U.S. 

 

	 	2.11	 “Indication” means a class of human disease or condition for which a separate NDA
(including any extensions or supplements) is required to be filed with the FDA. For clarity, if an NDA is approved for a Licensed Product in a particular Indication and patient population, a label expansion for such
Licensed Product to include such Indication in a different patient population shall not be considered a separate Indication. 

  

	 	2.12	 “Licensed Fields of Use” means the fields of use identified in Appendix B.

  

	 	2.13	 “Licensed Patent Rights” means: 

 

	 	(a)	 Patent applications (including provisional patent applications and PCT patent applications) or patents listed
in Appendix A, all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of these patents; 

 

	 	(b)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in Paragraph 2.13(a): 

  

	 	(i)	 continuations-in-part of
Paragraph 2.13(a); 

  

	 	(ii)	 all divisions and continuations of these
continuations-in-part; 

  

	 	(iii)	 all patents issuing from these
continuations-in-part, divisions, and continuations; 

  

	 	(iv)	 priority patent application(s) of Paragraph 2.13(a); and 

 

	 	(v)	 any reissues, reexaminations, and extensions of these patents; 

 

	 	(f)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in Paragraph 2.13(a): all counterpart foreign and U.S. patent applications and patents to Paragraphs 2.13(a) and 2.13(b), including those listed in Appendix A; and 

 

	 	(g)	 Licensed Patent Rights shall not include Paragraph 2.13(b) or Paragraph 2.13(c) to the extent
that they contain one or more claims directed to new matter which is not the subject matter disclosed in Paragraph 2.13(a). 

  

	 	2.14	 “Licensed Processes” means processes which, in the course of being practiced, would be within
the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction. 

	 	2.15	 “Licensed Products” means tangible materials which, in the course of manufacture, use, sale,
or importation, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.

  

	 	2.16	 “Licensed Territory” means the geographical area identified in Appendix B.

  

	 	2.17	 “NDA” means a New Drug Application of a Licensed Product filed with the FDA that
is required for marketing approval for such Licensed Product in the U.S. 

  

	 	2.18	 “Net Sales” means, with respect to any Licensed Product or Licensed Process, the
total gross receipts for sales of Licensed Products or practice of Licensed Processes by or on behalf of the Licensee or any of its Affiliates or its sublicensees to Third Parties, and from leasing, renting, or
otherwise making the Licensed Products available to Third Parties without sale or other dispositions, whether invoiced or not, less the following: [***]. No deductions shall be made for commissions paid to individuals, whether they are
with independent sales agencies or regularly employed by the Licensee, or any sublicensee, and on its payroll, or for the cost of collections. Notwithstanding the foregoing, sales among Licensee, its Affiliates, or their
respective sublicensees shall not be included in the calculation of Net Sales, unless the purchaser is an end user of the Licensed Product or Licensed Process. The supply of Licensed Product or practice of Licensed
Process as samples for charitable or promotional purposes, for use in non-clinical or clinical trials, or any test or other studies reasonably necessary to comply with any applicable laws, or as is
otherwise normal and customary in the industry shall not be included in the computation of Net Sales. 

  

	 	2.19	 “Practical Application” means to manufacture in the case of a composition or product, to
practice in the case of a process or method, or to operate in the case of a machine or system; and in each case, under these conditions as to establish that the invention is being utilized and that its benefits are to the extent permitted by law or
Government regulations available to the public on reasonable terms. 

  

	 	2.20	 “Pro Rata Share” means one of the following: 

 

	 	(a)	 in instances where the Additional License(s) granted by IC recover a pre-determined percentage of patent costs, [one hundred percent (100%) of patent prosecution costs minus the percentage of patent prosecution costs recovered by the Additional License(s)] which recover a pre-determined percentage of patent costs. For example, if IC has granted an Additional License [***], then the Pro Rata Share would be [***]; 

 

	 	(b)	 in instances where the Additional Licenses granted by IC recover a full pro rata share of patent
prosecution costs, [***] granted by IC which recover a full pro rata share of patent prosecution costs [***] granted by IC which recover a full pro rata share of patent prosecution costs. For example, if IC has granted
[***] which recover a full Pro Rata Share of patent prosecution costs, then the Pro Rata Share would be, [***], or [***]; or 

  

	 	(c)	 in instances where the Additional Licenses are granted according to the definition of both
Paragraphs 2.20(a) and 2.20(b), the Pro Rata Share paid by Licensee will be the value derived from the Pro Rata Share [***] the value derived from the Pro Rata Share [***]. For example, if two (2) Additional
Licenses are granted wherein one (1) Additional License recovers [***] of patent prosecution costs and one (1) Additional License recovers a full pro rata share of patent prosecution costs, the Pro Rata Share would
be [***]. 

	 	2.21	 “Research License” means a nontransferable, nonexclusive license to make and to use the
Licensed Products or the Licensed Processes as defined by the Licensed Patent Rights for purposes of research and not for purposes of commercial manufacture or distribution or in lieu of purchase. 

 

	 	2.22	 “Sublicense Royalties” means the fair market value of all consideration, in whatever form,
actually received from a Third Party sublicensee as consideration for the grant of a sublicense of the Licensed Patents Rights, excluding [***]. 

 

	 	2.23	 “Third Party” means a person or entity other than (i) Licensee or any of its
Affiliates or sublicensees and (ii) IC. 

  

	3.	 GRANT OF RIGHTS 

 

	 	3.1	 The IC hereby grants and the Licensee accepts, subject to the terms and conditions of this
Agreement, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the
Licensed Fields of Use and to practice and have practiced any Licensed Process(es) in the Licensed Fields of Use. 

  

	 	3.2	 This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent
applications or patents of the IC other than the Licensed Patent Rights regardless of whether these patents are dominant or subordinate to the Licensed Patent Rights. 

 

	4.	 SUBLICENSING 

  

	 	4.1	 [***], the Licensee may enter into sublicensing agreements under the Licensed Patent Rights.

  

	 	4.2	 The Licensee agrees that any sublicenses granted by it shall provide that the obligations to the
IC of Paragraphs 5.1-5.4, 8.1, 10.1, 10.2, 12.5, and 13.8-13.10 of this Agreement shall be binding upon the sublicensee as if it were a party to this
Agreement, to the extent applicable to the scope of the sublicense. The Licensee further agrees to attach copies of these Paragraphs to all sublicense agreements. 

 

	 	4.3	 Any sublicenses granted by the Licensee shall provide for the termination of the sublicense, or the
conversion to a license directly between the sublicensees and the IC, at the option of the sublicensee, upon termination of this Agreement under Article 13. This conversion is subject to the IC approval (not to be unreasonably
withheld, conditioned, or delayed) and contingent upon acceptance by the sublicensee of the remaining provisions of this Agreement, to the extent applicable to the scope of the sublicense. 

 

	 	4.4	 The Licensee agrees to forward to the IC a complete copy of each fully executed sublicense
agreement postmarked within [***] of the execution of the agreement; provided that Licensee may redact any commercially sensitive information which is not necessary for the IC to confirm (a) such sublicense agreement’s
compliance with the terms of this Agreement or (b) the Sublicense Royalties due under this Agreement, and provided that IC shall have the right to require Licensee to provide redacted information that it
reasonably believes is necessary to confirm either sublicensee’s compliance with the Agreement or the amount of Sublicense Royalties due under the Agreement. To the extent permitted by law, the IC agrees to maintain
each sublicense agreement in confidence. 

	5.	 STATUTORY AND NIH REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS 

 

	 	5.1	 

  

	 	(a)	 the IC reserves on behalf of the Government an irrevocable, nonexclusive, nontransferable,
royalty-free license for the practice of all inventions licensed under the Licensed Patent Rights throughout the world by or on behalf of the Government and on behalf of any foreign government or international organization pursuant to
any existing or future treaty or agreement to which the Government is a signatory. Prior to the First Commercial Sale, at the IC’s reasonable request and to the extent available, the Licensee agrees to provide the
IC with reasonable quantities of the Licensed Products or materials made through the Licensed Processes for IC research use; and 

  

	 	(b)	 in the event that the Licensed Patent Rights are Subject Inventions made under CRADA, the
Licensee grants to the Government, pursuant to 15 U.S.C. §3710a(b)(1)(A), a nonexclusive, nontransferable, irrevocable, paid-up license to practice the Licensed Patent Rights or have
the Licensed Patent Rights practiced throughout the world by or on behalf of the Government. In the exercise of this license, the Government shall not publicly disclose trade secrets or commercial or financial information that
is privileged or confidential within the meaning of 5 U.S.C. §552(b)(4) or which would be considered as such if it had been obtained from a non-Federal party. Prior to the First Commercial Sale, at
the IC’s request and to the extent available, the Licensee agrees to provide the IC with reasonable quantities of the Licensed Products or materials made through the Licensed Processes for IC research
use. 

  

	 	5.2	 To the extent required under 35 U.S.C. §204, as amended, the Licensee agrees that products used or
sold in the United States embodying the Licensed Products or produced through use of the Licensed Processes shall be manufactured substantially in the United States, unless a written waiver is obtained in advance from the IC.

  

	 	5.3	 The Licensee acknowledges that the IC may enter into future CRADAs under the Federal
Technology Transfer Act of 1986 that relate to the subject matter of this Agreement. The Licensee agrees not to unreasonably deny requests for a Research License from future collaborators with the IC when acquiring these
rights is necessary in order to make a CRADA project feasible. The IC shall notify Licensee of any such CRADA and Licensee may request an opportunity to join as a party to the proposed CRADA.

  

	 	5.4	 

  

	 	(a)	 in addition to the reserved license of Paragraph 5.1, the IC reserves the right to grant Research
Licenses directly or to require the Licensee to grant Research Licenses on reasonable terms. The purpose of these Research Licenses is to encourage basic research, whether conducted at an academic or corporate facility. In
order to safeguard the Licensed Patent Rights, however, the IC shall consult with the Licensee before granting to commercial entities a Research License or providing to them research samples of materials made through the
Licensed Processes; and 

	 	(b)	 in exceptional circumstances, and in the event that the Licensed Patent Rights are Subject Inventions
made under a CRADA, the Government, pursuant to 15 U.S.C. §3710a(b)(1)(B), retains the right to require the Licensee to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use
the Licensed Patent Rights in the Licensed Field of Use on terms that are reasonable under the circumstances, or if the Licensee fails to grant this license, the Government retains the right to grant the license itself.
The exercise of these rights by the Government shall only be in exceptional circumstances and only if the Government determines: 

  

	 	(i)	 the action is necessary to meet health or safety needs that are not reasonably satisfied by the
Licensee; 

  

	 	(ii)	 the action is necessary to meet requirements for public use specified by Federal regulations, and these
requirements are not reasonably satisfied by the Licensee; or 

  

	 	(iii)	 the Licensee has failed to comply with an agreement containing provisions described in 15 U.S.C.
§3710a(c)(4)(B); and 

  

	 	(c)	 the determination made by the Government under this Paragraph 5.4 is subject to administrative appeal
and judicial review under 35 U.S.C. §203(b). 

  

	6.	 ROYALTIES AND REIMBURSEMENT 

 

	 	6.1	 The Licensee agrees to pay the IC a noncreditable, nonrefundable license issue royalty as set
forth in Appendix C. 

  

	 	6.2	 The Licensee agrees to pay the IC a nonrefundable minimum annual royalty as set forth in Appendix
C. 

  

	 	6.3	 The Licensee agrees to pay the IC earned royalties as set forth in Appendix C.

  

	 	6.4	 The Licensee agrees to pay the IC benchmark royalties as set forth in Appendix C.

  

	 	6.5	 The Licensee agrees to pay the IC sublicensing royalties as set forth in Appendix C.

  

	 	6.6	 A patent or patent application licensed under this Agreement shall cease to fall within the Licensed
Patent Rights for the purpose of computing earned royalty payments in any given country on the earliest of the dates that: 

  

	 	(a)	 the application has been abandoned and not continued; 

 

	 	(b)	 the patent expires or irrevocably lapses has been revoked, disclaimed or admitted to be invalid or
unenforceable through reissue, re-examination, disclaimer or otherwise; or 

  

	 	(c)	 the patent has been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of
competent jurisdiction or administrative agency. 

  

	 	6.7	 No multiple royalties shall be payable because any Licensed Products or Licensed Processes are
covered by more than one of the Licensed Patent Rights. 

  

	 	6.8	 On sales of the Licensed Products by the Licensee made in other than an arm’s-length transaction, the value of the Net Sales attributed under this Article 6 to this transaction shall be that which would have been received in an
arm’s-length transaction in the same country, based on sales of like quantity and quality products in the same country on or about the time of this transaction. 

	 	6.9	 With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of
all patent applications and patents included within the Licensed Patent Rights and paid by the IC prior to the effective date of this Agreement, the Licensee shall pay the IC, as an additional royalty, within [***]
of the IC’s submission of a statement and request for payment to the Licensee, an amount equivalent to the unreimbursed patent expenses previously paid by the IC. 

 

	 	6.10	 With regard to expenses associated with the preparation, filing, prosecution, and maintenance of all patent
applications and patents included within the Licensed Patent Rights and paid by the IC on or after the effective date of this Agreement, the IC, at its sole option, may require the Licensee: 

 

	 	(a)	 to pay the IC on an annual basis, within [***] of the IC’s submission of a statement and
request for payment, a royalty amount equivalent to a Pro Rata Share of these expenses paid during the previous calendar year(s); 

  

	 	(b)	 to pay a Pro Rata Share of these expenses directly to the law firm employed by the IC to handle
these functions. However, in this event, the IC and not the Licensee shall be the client of the law firm; or 

  

	 	(c)	 in limited circumstances, the Licensee may be given the right, but not the obligation, to assume
responsibility for the preparation, filing, prosecution, or maintenance of any patent application or patent included in the Licensed Patent Rights. In that event, the Licensee shall directly pay the attorneys or agents engaged to
prepare, file, prosecute, or maintain these patent applications or patents and shall provide the IC with copies of each invoice associated with these services as well as documentation that these invoices have been paid. 

 

	 	6.11	 The IC agrees, upon written request, to provide the Licensee with summaries of patent prosecution
invoices for which the IC has requested payment from the Licensee under Paragraphs 6.9 and 6.10. The Licensee agrees that all information provided by the IC related to patent prosecution costs shall be treated as
confidential commercial information and shall not be released to a Third Party except as required by law or a court of competent jurisdiction. 

  

	 	6.12	 The Licensee may elect to surrender its rights in any country of the Licensed Territory under any
of the Licensed Patent Rights upon [***] written notice to the IC and owe no payment obligation under Paragraph 6.10 for patent-related expenses paid in that country after [***] of the effective date of the written notice.

  

	7.	 PATENT FILING, PROSECUTION, AND MAINTENANCE 

 

	 	7.1	 Except as otherwise provided in this Article 7, the IC agrees to take responsibility for, but to consult
with, the Licensee in the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights and shall furnish copies of relevant patent-related documents to the
Licensee. 

  

	 	7.2	 Upon the IC’s written request, the Licensee shall assume the responsibility for the
preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights and shall, on an ongoing basis, promptly furnish copies of all patent-related documents to the IC.
In this event, the Licensee shall, subject to the prior approval of the IC, select registered patent attorneys or patent agents to provide these services on behalf of the Licensee and the IC. The IC shall provide
appropriate powers of attorney and other documents necessary to undertake this action to the patent attorneys or patent agents providing these services. The Licensee and its attorneys or agents shall consult with the IC in all aspects
of the preparation, filing, prosecution and maintenance of patent applications and patents included within the Licensed Patent Rights and shall provide the IC sufficient opportunity to comment on any document that the Licensee
intends to file or to cause to be filed with the relevant intellectual property or patent office. 

	 	7.3	 At any time, the IC may [***] the preparation, filing, prosecution, and maintenance of any and all
patent applications or patents included in the Licensed Patent Rights. If the IC elects to [***], the Licensee agrees to cooperate fully with the IC, its attorneys, and agents in the preparation, filing, prosecution, and
maintenance of any and all patent applications or patents included in the Licensed Patent Rights and to provide the IC with complete copies of any and all documents or other materials that the IC deems necessary to undertake
such responsibilities. The [***] shall be responsible for all costs associated with transferring patent prosecution responsibilities to an attorney or agent of the IC’s choice. 

 

	 	7.4	 Each party shall promptly inform the other as to all matters that come to its attention that may affect the
preparation, filing, prosecution, or maintenance of the Licensed Patent Rights and permit each other to provide comments and suggestions with respect to the preparation, filing, prosecution, and maintenance of the Licensed Patent
Rights, which comments and suggestions shall be considered by the other party. 

  

	8.	 RECORD KEEPING 

 

	 	8.1	 The Licensee agrees to keep accurate and correct records of the Licensed Products made, used,
sold, or imported and the Licensed Processes practiced under this Agreement appropriate to determine the amount of royalties due the IC. These records shall be retained for at least [***] following a given reporting period and
shall be available during normal business hours for inspection, at the expense of the IC, by an accountant or other designated auditor selected by the IC and reasonably acceptable to Licensee for the sole purpose of verifying
reports and royalty payments hereunder. The IC may conduct such audits no more than once per calendar year, and may inspect records from a particular reporting period only once. The accountant or auditor shall sign Licensee’s
standard confidentiality agreement prior to the inspection and shall only disclose to the IC information relating to the accuracy of reports and royalty payments made under this Agreement. If an inspection shows an underreporting or
underpayment in excess of [***] for any [***] period, then the Licensee shall reimburse the IC for the cost of the inspection at the time the Licensee pays the unreported royalties, including any additional royalties as required
by Paragraph 9.8. All royalty payments required under this Paragraph shall be due within [***] of the date the IC provides to the Licensee notice of the payment due. If any inspection shows an overpayment by Licensee for any
period, then Licensee shall be permitted to credit the amount of such overpayment against any future amounts owed by Licensee under this Agreement. 

 

	9.	 REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS 

 

	 	9.1	 Prior to signing this Agreement, the Licensee has provided the IC with the Commercial
Development Plan in Appendix E, under which the Licensee intends to bring the subject matter of the Licensed Patent Rights to the point of Practical Application. This Commercial Development Plan is hereby incorporated
by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D. 

	 	9.2	 The Licensee shall provide written annual reports on its product development progress or efforts to
commercialize under the Commercial Development Plan for each of the Licensed Fields of Use within [***] after December 31 of each calendar year. These progress reports shall include, but not be limited to: progress on research and
development, status of applications for regulatory approvals, manufacture and status of sublicensing, marketing, importing, and sales during the preceding calendar year, as well as, plans for the present calendar year. The IC also encourages
these reports to include information on any of the Licensee’s public service activities that relate to the Licensed Patent Rights. If [***], the Licensee shall [***]. In any annual report, the Licensee may propose
amendments to the Commercial Development Plan, acceptance of which by the IC may not be denied unreasonably. The Licensee agrees to [***] by the IC to evaluate the Licensee’s performance under this
Agreement. The Licensee may amend the Benchmarks at any time upon written approval by the IC. The IC shall not unreasonably withhold approval of any request of the Licensee to extend the time periods of this
schedule if the request is supported by a reasonable showing by the Licensee of diligence in its performance under the Commercial Development Plan and toward bringing the Licensed Products to the point of Practical
Application as defined in 37 C.F.R. §404.3(d). The Licensee shall [***] in the plan originally submitted. 

  

	 	9.3	 The Licensee shall report to the IC the dates for achieving Benchmarks specified in
Appendix D and the First Commercial Sale in each country in the Licensed Territory within [***] of such occurrences. 

  

	 	9.4	 The Licensee shall submit to the IC, within [***] after each calendar half-year ending
June 30 and December 31, a royalty report, as described in the example in Appendix F, setting forth for the preceding half-year period the amount of the Licensed Products sold or Licensed Processes practiced by or on behalf
of the Licensee in each country within the Licensed Territory, the Net Sales, and the amount of royalty accordingly due. With each royalty report, the Licensee shall submit payment of earned royalties due. If no earned
royalties are due to the IC for any reporting period, the written report shall so state. The royalty report shall be certified as correct by an authorized officer of the Licensee and shall include a detailed listing of all deductions
made under Paragraph 2.18 to determine Net Sales made under Article 6 to determine royalties due. The royalty report shall also [***] for the Licensed Product(s) sold in the United States. 

 

	 	9.5	 The Licensee agrees to forward semi-annually to the IC a copy of these reports received by the
Licensee from its sublicensees during the preceding half-year period as shall be pertinent to a royalty accounting to the IC by the Licensee for activities under the sublicense. 

 

	 	9.6	 Royalties due under Article 6 shall be paid in U.S. dollars and payment options are listed in Appendix G. For
conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York foreign exchange rate quoted in The Wall Street Journal on the day that the payment is due. Any loss of exchange, value, taxes, or other expenses
incurred in the transfer or conversion to U.S. dollars shall be paid entirely by the Licensee. The royalty report required by Paragraph 9.4 shall be mailed to the IC at its address for Agreement Notices indicated on the
Signature Page. 

  

	 	9.7	 The Licensee shall be solely responsible for determining if any tax on royalty income is owed outside
the United States and shall pay the tax and be responsible for all filings with appropriate agencies of foreign governments. 

  

	 	9.8	 Additional royalties may be assessed by the IC on any payment that is more than [***] overdue at the
rate of [***] per month or, if lower, the maximum rate permitted by applicable law. This [***] per month rate may be applied retroactively from the original due date until the date of receipt by the IC of the overdue payment and additional
royalties. The payment of any such additional royalties shall not prevent the IC from exercising any other rights it may have as a consequence of the lateness of any payment. 

	 	9.9	 All plans and reports required by this Article 9 and marked “confidential” by the Licensee
shall, to the extent permitted by law, be treated by the IC as commercial and financial information obtained from a person and as privileged and confidential, and any proposed disclosure of these records by the IC under the Freedom of
Information Act (FOIA), 5 U.S.C. §552 shall be subject to the predisclosure notification requirements of 45 C.F.R. §5.65(d). 

  

	10.	 PERFORMANCE 

  

	 	10.1	 The Licensee shall use its reasonable commercial efforts to bring the Licensed Products and the
Licensed Processes to Practical Application. “Reasonable commercial efforts” for the purposes of this provision shall include adherence to the Commercial Development Plan in Appendix E and performance of the
Benchmarks in Appendix D. The efforts of any Affiliate or a sublicensee shall be considered the efforts of the Licensee. 

  

	 	10.2	 Upon the First Commercial Sale, until the expiration or termination of this Agreement, the
Licensee shall use its reasonable commercial efforts to make the Licensed Products and the Licensed Processes reasonably accessible to the United States public. 

 

	 	10.3	 The Licensee agrees, after its First Commercial Sale, to make commercially reasonable quantities
of the Licensed Products or materials produced through the use of the Licensed Processes available to patient assistance programs. 

  

	 	10.4	 The Licensee agrees, after its First Commercial Sale and as part of its marketing and product
promotion, to develop educational materials (e.g., brochures, website, etc.) directed to patients and physicians detailing the Licensed Products or medical aspects of the prophylactic and therapeutic uses of the Licensed Products.

  

	 	10.5	 The Licensee agrees to supply, upon the IC’s request, to the Mailing Address for
Agreement Notices indicated on the Signature Page, the Office of Technology Transfer, NIH with inert samples of the Licensed Products or the Licensed Processes or their packaging for educational and display purposes only.

  

	11.	 INFRINGEMENT AND PATENT ENFORCEMENT 

 

	 	11.1	 The IC and the Licensee agree to notify each other promptly of each infringement or possible
infringement of the Licensed Patent Rights, as well as, any facts which would be reasonably expected to affect the validity, scope, or enforceability of the Licensed Patent Rights of which either party becomes aware.

  

	 	11.2	 Pursuant to this Agreement and the provisions of 35 U.S.C. Chapter 29, the Licensee may:

  

	 	(a)	 bring suit in its own name, at its own expense, and on its own behalf for infringement of presumably valid
claims in the Licensed Patent Rights; 

  

	 	(b)	 in any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature
recoverable for the infringement; or 

  

	 	(c)	 settle any claim or suit for infringement of the Licensed Patent Rights provided, however, that the
IC and appropriate Government authorities shall have the first right to take such actions; and 

	 	(d)	 if the Licensee desires to initiate a suit for patent infringement, the Licensee shall notify the
IC in writing. If the IC does not notify the Licensee of its intent to pursue legal action within [***], the Licensee shall be free to initiate suit. The IC shall have a continuing right to intervene in the suit.
The Licensee shall take no action to compel the Government either to initiate or to join in any suit for patent infringement. The Licensee may request the Government to initiate or join in any suit if necessary to avoid
dismissal of the suit. Should the Government be made a party to any suit, [***] any costs, expenses, or fees which the Government incurs as a result of the motion or other action, including all costs incurred by the Government
in opposing the motion or other action. In all cases, the Licensee agrees to keep the IC reasonably apprised of the status and progress of any litigation. Before the Licensee commences an infringement action, the Licensee
shall notify the IC and give careful consideration to the views of the IC and to any potential effects of the litigation on the public health in deciding whether to bring suit. If the Licensee elects not to bring an action to
enforce any Licensed Patent Rights against any infringement, the IC, at its option, may do so at its own expense. 

  

	 	11.5	 In the event that a declaratory judgment action alleging invalidity or
non-infringement of any of the Licensed Patent Rights shall be brought against the Licensee or raised by way of counterclaim or affirmative defense in an infringement suit brought by the
Licensee under Paragraph 11.2, pursuant to this Agreement and the provisions of 35 U.S.C. Chapter 29 or other statutes, the Licensee may: 

 

	 	(a)	 defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the
Licensed Patent Rights; 

  

	 	(b)	 in any suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and awards of
whatever nature recoverable for the infringement; and 

  

	 	(c)	 settle any claim or suit for declaratory judgment involving the Licensed Patent Rights-provided,
however, that the IC and appropriate Government authorities shall have the first right to take these actions and shall have a continuing right to intervene in the suit; and 

 

	 	(d)	 if the IC does not notify the Licensee of its intent to respond to the legal action within a
reasonable time, the Licensee shall be free to do so. The Licensee shall take no action to compel the Government either to initiate or to join in any declaratory judgment action. The Licensee may request the
Government to initiate or to join any suit if necessary to avoid dismissal of the suit. Should the Government be made a party to any suit by motion or any other action of the Licensee, the Licensee shall reimburse the
Government for any costs, expenses, or fees, which the Government incurs as a result of the motion or other action. If the Licensee elects not to defend against the declaratory judgment action, the IC, at its option, may
do so at its own expense. In all cases, the Licensee agrees to keep the IC reasonably apprised of the status and progress of any litigation. Before the Licensee commences an infringement action, the Licensee shall notify
the IC and give careful consideration to the views of the IC and to any potential effects of the litigation on the public health in deciding whether to bring suit. 

 

	 	11.5	 In any action under Paragraphs 11.2 or 11.3 the expenses including costs, fees, attorney fees, and
disbursements, shall be paid by the Licensee. The value of any recovery made by the Licensee through court judgment or settlement shall be [***]. 

	 	11.6	 The IC shall cooperate fully with the Licensee in connection with any action under Paragraphs
11.2 or 11.3. The IC agrees promptly to provide access to all necessary documents and to render reasonable assistance in response to a request by the Licensee. 

 

	12.	 NEGATION OF WARRANTIES AND INDEMNIFICATION 

 

	 	12.1	 The IC offers no warranties other than those specified in Article 1. 

 

	 	12.2	 The IC does not warrant the validity of the Licensed Patent Rights and makes no representations
whatsoever with regard to the scope of the Licensed Patent Rights, or that the Licensed Patent Rights may be exploited without infringing other patents or other intellectual property rights of third parties. 

 

	 	12.3	 THE IC MAKES NO WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE
OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE LICENSED PATENT RIGHTS OR TANGIBLE MATERIALS RELATED THERETO. 

  

	 	12.4	 The IC does not represent that it shall commence legal actions against third parties infringing the
Licensed Patent Rights. 

  

	 	12.5	 The Licensee shall indemnify and hold the IC, its employees, students, fellows, agents, and
consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of: 

 

	 	(a)	 the use by or on behalf of the Licensee, its sublicensees, directors, employees, or third parties of any
Licensed Patent Rights; or 

  

	 	(b)	 the design, manufacture, distribution, or use of any Licensed Products, Licensed Processes or
materials by the Licensee, or other products or processes developed by Licensee or its sublicensees in connection with or arising out of the Licensed Patent Rights. 

except to the extent arising out of the IC’s breach of this Agreement or the gross negligence or willful misconduct of the
IC or any its employees, students, fellows, agents, or consultants. 
  

	 	12.3	 The Licensee agrees to maintain a liability insurance program consistent with sound business practice.

  

	13.	 TERM, TERMINATION, AND MODIFICATION OF RIGHTS 

13.1 This Agreement is effective when signed by all parties, unless the provisions of Paragraph 14.16 are not fulfilled, and shall
extend, on a Licensed Product-by-Licensed Product (or Licensed Process-by-Licensed Process) and country-by-country basis, to the expiration
of the last to expire of the Licensed Patent Rights that claims such Licensed Product (or Licensed Process) in such country unless sooner terminated as provided in this Article 13. 

13.2 In the event that the Licensee is in default in the performance of any material obligations under this Agreement, including
but not limited to the obligations listed in Paragraph 13.5, and if the default has not been remedied within ninety (90) days after the date of notice in writing of the default, the IC may terminate this Agreement by written
notice and pursue outstanding royalties owed through procedures provided by the Federal Debt Collection Act. 

	 	13.3	 In the event that the Licensee becomes insolvent, files a petition in bankruptcy, has such a petition
filed against it, determines to file a petition in bankruptcy, or receives notice of a third party’s intention to file an involuntary petition in bankruptcy, the Licensee shall immediately notify the IC in writing.

  

	 	13.4	 The Licensee shall have a unilateral right to terminate this Agreement or any licenses in any
country or territory by giving the IC sixty (60) days written notice to that effect. 

  

	 	13.5	 The IC shall specifically have the right to terminate or modify, at its option, this Agreement,
if the IC reasonably determines that the Licensee: 

  

	 	(a)	 is not executing the Commercial Development Plan submitted with its request for a license, as may be
amended pursuant to Paragraph 9.2, and the Licensee cannot otherwise demonstrate to the IC’s satisfaction that the Licensee has taken, or can be expected to take within a reasonable time, effective steps to achieve the
Practical Application of the Licensed Products or the Licensed Processes; 

  

	 	(b)	 has not achieved the Benchmarks as may be modified under Paragraph 9.2; 

 

	 	(c)	 has willfully made a false statement of, or willfully omitted a material fact in the license application or in
any report required by this Agreement; 

  

	 	(d)	 has committed a material breach of a covenant or agreement contained in this Agreement;

  

	 	(e)	 is not keeping the Licensed Products or the Licensed Processes reasonably available to the public
after commercial use commences; 

  

	 	(f)	 cannot reasonably satisfy unmet health and safety needs; 

 

	 	(g)	 cannot reasonably justify a failure to comply with the domestic production requirement of Paragraph 5.2 unless
waived; or 

  

	 	(h)	 has been found by a court of competent jurisdiction to have violated the Federal antitrust laws in connection
with its performance under this Agreement. 

  

	 	13.6	 In making the determination referenced in Paragraph 13.5, the IC shall take into account the normal
course of such commercial development programs conducted with sound and reasonable business practices and judgment and the annual reports submitted by the Licensee under Paragraph 9.2. Prior to invoking termination or modification of this
Agreement under Paragraph 13.5, the IC shall give written notice to the Licensee providing the Licensee specific notice of, and a ninety (90) day opportunity to respond to, the IC’s concerns as to the
items referenced in 13.5(a)-13.5(g). If the Licensee fails to alleviate the IC’s concerns as to the items referenced in 13.5(a)-13.5(g)or fails to
initiate corrective action to the IC’s satisfaction, the IC may terminate this Agreement  

  

	 	13.7	 When the public health and safety so require, and after written notice to the Licensee providing the
Licensee a [***] opportunity to respond, the IC shall have the right to require the Licensee to grant sublicenses to responsible applicants, on reasonable terms, in any Licensed Fields of Use under the Licensed Patent
Rights, unless the Licensee can reasonably demonstrate that the granting of the sublicense would not materially increase the availability to the public of the subject matter of the Licensed Patent Rights. The IC shall not
require the granting of a sublicense unless the responsible applicant has first negotiated in good faith with the Licensee. 

	 	13.8	 The IC reserves the right according to 35 U.S.C. §209(d)(3) to terminate or modify this
Agreement if it is determined that this action is necessary to meet the requirements for public use specified by federal regulations issued after the date of the license and these requirements are not reasonably satisfied by the
Licensee. 

  

	 	13.9	 Within [***] of receipt of written notice of the IC’s [***] to modify or terminate this
Agreement, the Licensee may, consistent with the provisions of 37 C.F.R. §404.11, appeal the decision by written submission to the designated IC official or designee. The decision of the designated IC official or
designee shall be the final agency decision. The Licensee may thereafter exercise any and all administrative or judicial remedies that may be available. 

 

	 	13.10	 Within [***] of expiration or termination of this Agreement under this Article 13, a final report shall
be submitted by the Licensee. Any royalty payments, including those incurred but not yet paid (such as the full minimum annual royalty), and those related to patent expenses, due to the IC shall become immediately due and payable upon
termination or expiration. If terminated under this Article 13, sublicensees may elect to convert their sublicenses to direct licenses with the IC pursuant to Paragraph 4.3. Unless otherwise specifically provided for under this
Agreement, upon termination or expiration of this Agreement, the Licensee shall return all Licensed Products, or other materials included within the Licensed Patent Rights to the IC or provide the IC
with written certification of the destruction thereof. The Licensee may not be granted additional IC licenses if the final reporting requirement is not fulfilled. 

 

	14.	 GENERAL PROVISIONS 

 

	 	14.1	 Neither party may waive or release any of its rights or interests in this Agreement except in writing.
The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right by such party or excuse a similar subsequent failure to perform any
of these terms or conditions by the other party. 

  

	 	14.2	 This Agreement constitutes the entire agreement between the parties relating to the subject matter of
the Licensed Patent Rights, the Licensed Products and the Licensed Processes, and all prior negotiations, representations, agreements, and understandings are merged into, extinguished by, and completely expressed by this
Agreement. 

  

	 	14.3	 The provisions of this Agreement are severable, and in the event that any provision of this
Agreement shall be determined to be invalid or unenforceable under any controlling body of law, this determination shall not in any way affect the validity or enforceability of the remaining provisions of this Agreement.

  

	 	14.4	 If either party desires a modification to this Agreement, the parties shall, upon reasonable notice of
the proposed modification by the party desiring the change, confer in good faith to determine the desirability of the modification. No modification shall be effective until a written amendment is signed by the signatories to this Agreement or
their designees. 

  

	 	14.5	 The construction, validity, performance, and effect of this Agreement shall be governed by Federal law
as applied by the Federal courts in the District of Columbia. 

  

	 	14.6	 All Agreement notices required or permitted by this Agreement shall be in writing and given by
prepaid, first class, registered or certified mail or by an express/overnight delivery service provided by a commercial carrier, properly addressed to the other party at the address designated on the following Signature Page, or to another address
as may be designated in writing by such other party. Agreement notices shall be considered timely if such notices are received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal
Service postmark or dated receipt from a commercial carrier. Parties should request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be
acceptable as proof of timely mailing. 

	 	14.7	 This Agreement shall not be assigned or otherwise transferred (including any transfer by legal process or by
operation of law, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure or order of court) except to the Licensee’s Affiliate(s) (for which the consent of IC shall not be required), without the prior written consent
of the IC, not to be unreasonably withheld, conditioned or delayed. For any assignment other than to an Affiliate the IC will have a period of [***] from the date that it receives written notice from the Licensee of a proposed assignment, to approve
or reject the proposed assignment and such approval shall not be unreasonably withheld; the approval or rejection must be in writing and delivered to Licensee’s official address for Agreement notices. If the IC does not reject the proposed
assignment within the [***] period, the IC shall be deemed to have given its approval of such assignment and the Licensee shall have the right to enter into such assignment agreement. The parties agree that the identity of the parties is material to
the formation of this Agreement and that the obligations under this Agreement are nondelegable. In the event that the IC approves a proposed assignment, the Licensee shall [***] for any assignment of this Agreement within [***] of the assignment (it
being understood that [***] to this Agreement). 

  

	 	14.8	 The Licensee agrees in its use of any IC-supplied materials to comply with all applicable
statutes, regulations, and guidelines, including NIH and HHS regulations and guidelines. The Licensee agrees not to use the materials for research involving human subjects or clinical trials in the United States without
complying with 21 C.F.R. Part 50 and 45 C.F.R. Part 46. The Licensee agrees not to use the materials for research involving human subjects or clinical trials outside of the United States without notifying the IC, in writing, of the
research or trials and complying with the applicable regulations of the appropriate national control authorities. Written notification to the IC of such research involving human subjects or clinical trials outside of the United States shall
be given no later than [***] prior to commencement of the research or trials. 

  

	 	14.9	 The Licensee acknowledges that it is subject to and agrees to abide by the United States laws and
regulations (including the Export Administration Act of 1979 and Arms Export Control Act) controlling the export of technical data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of these items may
require a license from the appropriate agency of the U.S. Government or written assurances by the Licensee that it shall not export these items to certain foreign countries without prior approval of this agency. The IC neither
represents that a license is or is not required or that, if required, it shall be issued. 

  

	 	14.10	 The Licensee agrees to mark the Licensed Products or their packaging sold in the United States
with all applicable U.S. patent numbers and similarly to indicate “Patent Pending” status, to the extent required by applicable laws. All the Licensed Products manufactured in, shipped to, or sold in other countries shall be marked
in a manner to preserve the IC’s patent rights in those countries, except to acknowledge the grant of the license pursuant to this Agreement. 

 

	 	14.11	 By entering into this Agreement, the IC does not directly or indirectly endorse any product or
service provided, or to be provided, by the Licensee whether directly or indirectly related to this Agreement. The Licensee shall not state or imply that this Agreement is an endorsement by the Government, the
IC, any other Government organizational unit, or any Government employee. Additionally, the Licensee shall not use the names of the IC, the FDA or the HHS or the Government or their employees
in any advertising, promotional, or sales literature without the prior written approval of the IC. 

  

	 	14.12	 The parties agree to attempt to settle amicably any controversy or claim arising under this Agreement or
a breach of this Agreement, except for appeals of modifications or termination decisions provided for in Article 13. The Licensee agrees first to appeal any unsettled claims or controversies to the designated IC official, or
designee, whose decision shall be considered the final agency decision. Thereafter, the Licensee may exercise any administrative or judicial remedies that may be available. 

	 	14.13	 Nothing relating to the grant of a license, nor the grant itself, shall be construed to confer upon any person
any immunity from or defenses under the antitrust laws or from a charge of patent misuse, and the acquisition and use of rights pursuant to 37 C.F.R. Part 404 shall not be immunized from the operation of state or Federal law by reason of the source
of the grant. 

  

	 	14.14	 Any formal recordation of this Agreement required by the laws of any Licensed Territory as a
prerequisite to enforceability of the Agreement in the courts of any foreign jurisdiction or for other reasons shall be carried out by the Licensee at its expense, and appropriately verified proof of recordation shall be promptly
furnished to the IC. 

  

	 	14.15	 Paragraphs 4.3, 8.1, 9.5-9.8,
12.1-12.5, 13.9, 13.10, 14.12 and 14.15 of this Agreement shall survive termination of this Agreement. 

  

	 	14.16	 The terms and conditions of this Agreement shall, at the IC’s sole option, be considered by
the IC to be withdrawn from the Licensee’s consideration and the terms and conditions of this Agreement, and the Agreement itself to be null and void, unless this Agreement is executed
by the Licensee and a fully executed original is received by the IC within [***] from the date of the IC’s signature found at the Signature Page. 

SIGNATURES BEGIN ON NEXT PAGE 

 NIH PATENT LICENSE AGREEMENT – EXCLUSIVE 

SIGNATURE PAGE 
  

			
	For the IC:	  	
		
	 /s/ Richard U. Rodriguez-S
	  	2-5-21                
	Richard U. Rodriguez, M.B.A.	  	Date
	Associate Director
	Technology Transfer Center, NCI
	National Institutes of Health
	
	Mailing Address or E-mail Address for Agreement notices and reports:
	
	License Compliance and Administration
	Monitoring & Enforcement
	Office of Technology Transfer
	National Institutes of Health
	6011 Executive Boulevard, Suite 325
	Rockville, Maryland 20852-3804 U.S.A.
	
	E-mail: LicenseNotices_Reports@mail.nih.gov

 For the Licensee (Upon, information and belief, the undersigned expressly certifies or affirms that the contents of any
statements of the Licensee made or referred to in this document are truthful and accurate.): 
  

			
	by:	  	
		
	 /s/ Curt Herberts
	  	2/9/2021                
	Signature of Authorized Official	  	Date
		
	 Curt Herberts
	  	
	Printed Name	  	
		
	 CFO and CBO
	  	
	Title	  	

  

	 	I.	 Official and Mailing Address for Agreement notices: 

[***] 
  

	 	II.	 Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty
payments) 

 [***] 

Any false or misleading statements made, presented, or submitted to the Government, including any relevant omissions, under this
Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal
liability including fine(s) or imprisonment). 

 APPENDIX A – PATENT(S) OR PATENT APPLICATION(S) 

Patent(s) or Patent Application(s): 
  

	I.	
E-136-2012-0
Technology 

  

	 	a)	 U.S. Provisional Patent Application 61/654,232 entitled “High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof” [HHS Ref.
E-136-2012-0-US-01], 

 

	 	b)	 PCT Patent Application PCT/US2013/043633 entitled “High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof” [HHS Ref.
E-136-2012-0-PCT-02], 

 

	 	c)	 Chinese Patent 104520331 entitled “High-affinity Monoclonal Antibodies To
Glypican-3 And Use Thereof” [HHS Ref. E-136-2012-0-CN-03], 

  

	 	d)	 Japanese Patent 6494507 entitled “High-affinity Monoclonal Antibodies To
Glypican-3 And Use Thereof” [HHS Ref. E-136-2012-0-JP-04], 

  

	 	e)	 South Korean Patent Application 10-2014-7037046 entitled
“High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof” [HHS Ref. E-136-2012-0-KR-05], 

  

	 	f)	 Singapore Patent 11201407972R entitled “High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof” [HHS Ref.
E-136-2012-0-SG-06], and 

 

	 	g)	 United States Patent 9,409,994 entitled “High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof” [HHS Ref.
E-136-2012-0-US-07]. 

 APPENDIX B – LICENSED FIELDS OF USE AND TERRITORY 

 

	I.	 Licensed Fields of Use: 

The development, production and commercialization of a monospecific chimeric antigen receptor (CAR)-based immunotherapy for the prophylaxis and
treatment of GPC3-expressing human cancers using unmodified, allogeneic NK cells transduced with a viral vector that expresses a CAR, and a gene circuit regulating the expression of one or more armoring payloads, wherein: 

 

	 	1)	 the CAR includes: 

  

	 	a.	 a single antigen specificity comprising at least the complementary determining region (CDR) sequences of the
anti-GPC3 antibody known as YP7 and 

  

	 	b.	 an intracellular signaling domain; 

 

	 	2)	 [***] 

  

	 	3)	 [***] 

The Licensed Field of Use specifically excludes the use of autologous T cells or T cells that have been genetically modified to become
allogeneic. [***] 
  

	II.	 Licensed Territory: Worldwide 

 APPENDIX C – ROYALTIES 

Royalties: 
 I. The Licensee agrees to pay to the IC a
noncreditable, nonrefundable license issue royalty in the amount of two hundred and fifty thousand dollars ($250,000.00) [***]. 
 [***]. 

 APPENDIX D – BENCHMARKS AND PERFORMANCE 

[***] 

 APPENDIX E – COMMERCIAL DEVELOPMENT PLAN 

[***] 
 Figure 1: [***] 

 APPENDIX F – EXAMPLE ROYALTY REPORT 

Required royalty report information includes: 
  

	•	 License reference number
(L-XXX-200X/0) 

  

	•	 Reporting period 

  

	•	 Catalog number and units sold of each Licensed Product (domestic and foreign) 

 

	•	 Gross Sales per catalog number per country 

 

	•	 Total Gross Sales 

  

	•	 Itemized deductions from Gross Sales 

 

	•	 Total Net Sales 

  

	•	 Earned Royalty Rate and associated calculations 

 

	•	 Gross Earned Royalty 

 

	•	 Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made 

 

	•	 Net Earned Royalty due 

Example 
  

											
	 Catalog Number
	  	Product Name	  	Country	  	Units Sold	  	Gross Sales
(US$)	 
	 1
	  	A	  	US	  	250	  	 	62,500	 
	 1
	  	A	  	UK	  	32	  	 	16,500	 
	 1
	  	A	  	France	  	25	  	 	15,625	 
	 2
	  	B	  	US	  	0	  	 	0	 
	 3
	  	C	  	US	  	57	  	 	57,125	 
	 4
	  	D	  	US	  	12	  	 	1,500	 

  

					
	 Total Gross Sales
	  	 	153,250	
	 Less Deductions:
	  			
	 Freight
	  	 	3,000	
	 Returns
	  	 	7,000	
	 Total Net Sales
	  	 	143,250	
	 Royalty Rate
	  	 	8	% 
	 Royalty Due
	  	 	11,460	
	 Less Creditable Payments
	  	 	10,000	
	 Net Royalty Due
	  	 	1,460	

 APPENDIX G – ROYALTY PAYMENT OPTIONS 

New Payment Options Effective March 2018 

The License Number MUST appear on payments, reports and correspondence. 

Credit and Debit Card Payments: Credit and debit card payments can be submitted for amounts up to $24,999. Submit your payment through the U.S.
Treasury web site located at: https://www.pay.gov/public/form/start/28680443. 
 Automated Clearing House (ACH) for payments through U.S. banks
only 
 The IC encourages its licensees to submit electronic funds transfer payments through the Automated Clearing House (ACH). Submit your ACH
payment through the U.S. Treasury web site located at: https://www.pay.gov/public/form/start/28680443. Please note that the IC “only” accepts ACH payments through this U.S. Treasury web site. 

Electronic Funds Wire Transfers: The following account information is provided for wire payments. In order to process payment via
Electronic Funds Wire Transfer sender MUST supply the following information within the transmission: 
 Drawn on a U.S. bank account via FEDWIRE:

 Please provide the following instructions to your Financial Institution for the remittance of Fedwire payments to the NIH ROYALTY FUND.

 [***] 
 Agency
Contacts:    Office of Technology Transfer (OTT)    [***] 
 Drawn on a foreign bank account via
FEDWIRE: 
 The following instructions pertain to the Fedwire Network. Deposits made in US Dollars (USD). 

Should your remitter utilize a correspondent US domestic bank in transferring electronic funds, the following Fedwire instructions are applicable. 

[***] 

 Agency Contacts: 
  

			
	Office of Technology Transfer (OTT)	  	[***]

 Checks 
 All checks
should be made payable to “NIH Patent Licensing” 
 Checks drawn on a U.S. bank account and sent by US Postal Service should be sent
directly to the following address: 
 [***] 

Checks drawn on a U.S. bank account and sent by overnight or courier should be sent to the following address: 

[***] 
 Checks drawn on a foreign bank
account should be sent directly to the following address: 
 [***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]